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ABSTRACT 
 
TITLE:  Doppler  ultrasound in  assessment  of  vascular  response to  primary  
systemic  chemotherapy in  locally  advanced  breast cancer. 
OBJECTIVE. To assess the response of tumor vascularity to primary systemic 
chemotherapy using doppler in patients with locally advanced breast cancer, and to 
compare it with morphological response  by clinical and sonographic assessment 
with histopathology as gold standard. 
MATERIAL AND METHODS: 54 patients with non-metastatic locally advanced 
breast cancer underwent detailed clinical examination, ultrasonography of breast 
and axillae, and color and spectral  doppler examination at baseline and before 
every cycle of chemotherapy (FAC regimen) to assess response to chemotherapy. 
Doppler indices(PSV, EDV, RI and PI) and tumor vascularity(no. of  colour 
signals) were recorded prior to every cycle. Assessment for operability was done at 
end of 4 cycles and patients were referred to surgical department for curative 
surgery. The results of clinical examination, ultrasonography and color doppler 
were compared with results obtained from histopathology. 
  
RESULTS: Doppler was able to predict the response to chemotherapy earlier in 
90% of cases. The best predictor for complete pathological response was found to 
be disappearance of all vascular signals within the tumor. A serial increase  in the  
RI of tumor vessels was found to very good in predicting complete pathological 
response with a sensitivity, specificity, PPV and NPV of 80%, 93.4%, 66.7% and 
95.6% respectively. There was no significant difference in doppler angle 
dependent  indices – PSV & EDV- between responders and non-responders 
 
CONCLUSION: Colour Doppler is a cost-effective method to assess response to 
chemotherapy in patients with locally advanced breast cancer. 
 
KEYWORDS : Locally advanced breast cancer, primary systemic chemotherapy, 
Doppler ultrasound, Resistivity Index. 
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INTRODUCTION 
Breast cancer is the most commonly occurring cancer in women and the 
most frequent cause of female cancer death in the world as a whole .Overall, in 
India, its incidence ranks second, next to that of  cervical cancer. But recently it 
has been found that it is the most common cancer in women in the metropolitan 
cities.
[1,2]
  The incidence rates are increasing and a higher proportion of newly 
diagnosed cases are in late stage of disease resulting in an increase in morbidity. 
Among those who present with locally advanced disease, the subset of 
patients who have metastatic disease can only be offered palliative therapy and 
their 5 year  survival rate is dismal (20%).
[3]
 Those  who have locally advanced 
disease but no evidence of systemic metastases, can be treated with an intent to 
cure. Since in our country 30- 60% of patients present with advanced stage and 
among them almost half have non metastatic locally advanced disease, disease 
mortality can be greatly reduced by proper management of these patients. 
The treatment options for locally advanced breast cancer include surgery 
followed by adjuvant chemotherapy and primary systemic chemotherapy 
(earlier known as neo adjuvant chemotherapy) followed by surgery with or 
without adjuvant chemotherapy and radiotherapy. Neoadjuvant chemotherapy is 
the norm now because it can downstage the tumour and convert inoperable 
tumours into operable ones thereby avoiding morbid, mutilating surgeries. 
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It has been proven that pathological complete response to primary 
systemic chemotherapy is a powerful predictor of prolonged disease free 
survival in patients with locally advanced breast cancer. But response to 
neoadjuvant chemotherapy is highly variable and ranges from 30-100%. Among 
patients with locally advanced breast cancer (LABC) around 3-20% do not 
respond to chemotherapy according to literature. 
If the response to chemotherapy can be predicted earlier during the course 
of the chemotherapy, we would be able to stop further administration of the 
chemotherapy regimen to people who are not responding, thereby saving these 
patients from the toxicity of the inefficacious chemotherapeutic agents. As of 
now, in India, clinical examination is the most widely used method to assess 
response to chemotherapy. Clinical examination and ultrasonography use 
morphological criteria, mainly change in size, to assess tumour response to 
treatment. 
Tumour vascularity has received much attention of late and it has been 
postulated that neoangiogenesis in tumours is an important phenomenon 
essential for the sustenance and proliferation of cancer cells. It has also been 
suggested that the tumour vessels may respond to chemotherapeutic agents even 
before there is significant reduction in tumour size. 
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Assessment of tumour vascularity can be done by Doppler ultrasound and 
dynamic contrast enhanced MRI. Studies on MRI done in the western world 
have revealed MRI has a very good accuracy in detecting response. But the 
expense involved in doing MRI is prohibitive when considered for application 
to a large number of people especially in a low income country like India. 
Doppler ultrasound is non invasive and less expensive and is therefore a more 
practical option in a developing country like ours. This prospective study was 
done with objective of ascertaining the usefulness of Doppler in predicting the 
response of LABC to neoadjuvant chemotherapy 
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AIMS AND OBJECTIVES 
1. To evaluate Doppler ultrasound parameters in assessment of vascular 
response to chemotherapy in patients with locally advanced breast cancer 
and to compare it with morphological response by clinical examination 
and ultrasound taking post-surgical histopathological response as gold 
standard 
2. To ascertain the ability of Doppler ultrasound to predict the response 
early during the course of chemotherapy. 
 
 
11 
 
REVIEW OF LITERATURE 
Breast cancer is on the rise worldwide including the developing world. It 
is a major cause of female cancer mortality. Since there is no structured 
screening programme to detect breast cancer in India and since the awareness 
among women is very low, breast cancer is not detected early in a vast majority 
of cases. So, the incidence of advanced breast cancer which includes non-
metastatic locally advanced and metastatic disease is much higher in developing 
countries than the western world.  
The 7th edition of AJCC cancer staging manual stages breast cancer as 
follows.
[4,5] 
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BREAST CANCER STAGING – AJCC MANUAL 7th EDITION 
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Locally advanced breast cancer essentially includes all stage IIIB and 
IIIC tumours along with a small subset of stage IIIA tumours. It is a 
heterogeneous entity including cases which have advanced disease either in 
a. primary tumour (T3 - tumours >5cm,  
      T4 - skin involvement, chest wall involvement and 
inflammatory tumours) 
b.  nodal stage (fixed ipsilateral axillary nodes, 
ipsilateral internal mammary nodes, 
ipsilateral infraclavicular nodes, 
ipsilateral supraclavicular nodes)  
c. Both 
All of these would fall under stage III except T3 N0 tumours which fall 
under stage IIB. These tumours are further classified as those that are operable 
and those that are inoperable.
[6] 
- Operable LABC – Stage IIB and IIIA (T3 and N2 tumours) 
- Inoperable LABC – Stage IIIB and IIIC (T4 and N3 tumours) 
Most invasive breast cancers are considered to be systemic diseases at 
diagnosis in lieu of micrometatases to distant sites. According to the guidelines 
published by National Collaborating Centre For Cancer at Wales, chemotherapy 
to eradicate micrometastases is indicated even in patients with early breast 
cancer based on the prognostic factors of the individual tumour.
[7]
 So, locally 
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advanced tumours require multimodality treatment for adequate disease 
control.
[8,9,10,11] 
The operable tumours have the option of undergoing curative surgery 
followed by adjuvant chemotherapy.  Neoadjuvant chemotherapy can also be 
used in such cases so as to reduce the tumour size, offer breast conservation and 
avoid mutilating surgeries. Neoadjuvant chemotherapy has been found to be 
atleast as effective as adjuvant therapy in the NSABP B-18 study, making either 
approach reasonable for a woman with operable breast cancer. The survival 
rates of women treated with adjuvant or neoadjuvant chemotherapy are 
equivalent.
[12] 
 
But in case of tumours that are inoperable at presentation, the option of 
primary surgery does not exist. Also, there is increased possibility of 
micrometastases. So, neoadjuvant chemotherapy followed by surgery with or 
without adjuvant chemotherapy and radiotherapy is the current norm for such 
patients.
[8]
 Neoadjuvant chemotherapy  is also very effective in downstaging the 
tumours rendering inoperable tumours operable.
[9,10] 
Primary systemic chemotherapy also has the advantages of delivery of 
drugs through intact vasculature and the opportunity to study the biologic 
effects of chemotherapy in vivo. Disadvantages are the resultant loss of 
important pathologic prognostic markers such as initial tumour size and the 
number of axillary lymph nodes involved.  
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There are several prognostic indices for breast cancer such as the 
histological grade, stage at presentation and receptor status. For tumours that 
have been treated with chemotherapy, response to chemotherapy is a powerful 
predictor of  disease free survival and it is the most commonly used one.
[13]
 In a 
study by Feldman et al, patients without gross residual tumour after 
chemotherapy had a survival rate at 6 years of 93% whereas those with residual 
tumour had a survival rate of only 34%.
[14]
 In a study by Chollet et al which 
included 451 patients, the difference in disease free survival among those 
patients who had achieved pathological complete response and those who had 
not was statistically significant with relapse rates being 18.3% in patients who 
attained pCR and 35.4% in patients who did not.
[15] 
Apart from the prognostic value, prediction of response to chemotherapy 
early during the chemotherapeutic regimen is of great practical value in the 
management of individual patients. If non responders are identified early, the 
remainder of the inefficacious regimen can be terminated, thereby protecting the 
patients from their unwanted toxic effects and alternative treatment strategies 
can be offered which could help in disease control in such patients. Such 
strategies include switching over to an alternative regimen of non-cross resistant  
chemotherapeutic drugs or early surgery. 
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The response to chemotherapy in individual tumours varies as breast 
cancer is a biologically heterogeneous entity. Needless to say the 
chemotherapeutic agent used also plays an important role in determining 
pathological response and thereby has a bearing on patient survival. The 
NSABP B-27 study and Aberdeen trial (TAX 301) reported better breast 
conservation rates and pathological complete response rates with addition of 
docetaxel to the chemotherapeutic regimen.
[16,17] 
 
Thus, assessment of response to chemotherapy plays an important role 
both in the management and prognostication of patients with breast cancer. 
Various methods of assessment have been studied by researchers worldwide. 
They can be summarised as follows 
1. Clinical assessment 
2. Laboratory assessment 
 - Histopathological markers like tumour grade, receptor status and 
expression of angiogenic markers like VEGF, CD-105. 
 - Serum biomarkers like MIF, MMP-2, EGFR 
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3. Imaging 
 - Morphological imaging: X Ray mammography, B mode 
ultrasound, Computed Tomography, Magnetic resonance 
imaging 
 - Functional imaging: 
1. Vascular imaging: Doppler ultrasound, Doppler ultrasound 
with micro bubble contrast agent, Dynamic contrast 
enhanced MRI 
2. Non vascular imaging: Diffuse Optical Spectroscopy, 
Positron Emission Spectroscopy, Mammoscintigraphy. 
 
CLINICAL EXAMINATION  
Clinical assessment is by far the most widely used method for evaluation 
of response to chemotherapy  in developing countries like ours. It is easily 
available, inexpensive and less time consuming. But it has been found to be 
inaccurate in many studies. Khokher et al have concluded that sensitivity of 
initial clinical response to predict the clinical response at the end of 
chemotherapy were high at 91% and 83% respectively with an accuracy of 
83%. They also found that initial clinical progressive disease had very good 
sensitivity, specificity and accuracy for predicting clinically progressive disease 
at the end of chemotherapy. But the authors had not compared the correlation 
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between the initial or final clinical response with pathological response.
[18]
 
Other studies quoted later reveal that the correlation of clinical response with 
pathological response was neither consistently nor substantially significant. 
In a series of 141 patients, Fiorentino et al have reported that clinical 
examination was better in the prediction of complete pathological response and 
that it correlated significantly with disease free survival. But the authors had 
compared clinical examination only with morphological imaging modalities – 
mammography and ultrasound, and not with the newer functional imaging 
modalities.
[19] 
Von Minckwitz et al have reported in their study that patients with a 
clinical complete or partial response were 3.3 times more likely to achieve a 
pCR than those who did not. But they have also concluded that though the 
clinical response after two cycles is a strong predictor it is not independent.
[20] 
In a study by Cocconi et al, it was found that clinical assessment had a 
false positive rate of 22.9% and false negative rate of 8.9% in assessing 
response to chemotherapy.
[21]
 In a series of 141 patients, Sun et al found that the 
false complete remission rate as judged by clinical examination was 46.8%.
[22] 
Helvie et al have concluded that the sensitivity of clinical examination to 
identify residual tumor mass after neoadjuvant chemotherapy in 56 patients with 
LABC was only 49%.
[23] 
Chagpar et al in a study with 189 patients found that 
the correlation between clinical and pathological response was poor (Kappa 
value between 0.24 and 0.35).
[24]
 Similarly Yeh et al have found that the 
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agreement between clinical assessment and pathological assessment for 
response is only 19%.
[25] 
The disadvantage with clinical examination is that when sometimes the 
mass resolves on chemotherapy leaving behind viable tumour cells, it can 
become undetectable by palpation. Also the high rate of underestimation of 
response may be due the fact that palpation cannot differentiate between a 
fibrotic  or necrotic mass and viable residual tumour mass. This seems to be a 
significant fact as most tumours respond to chemotherapy by a process of 
fibrosis and necrosis. Also, tumour cell exposure to chemotherapeutic drugs like 
anthracyclines has been shown to induce immunostimulatory apoptosis and 
presentation of damage-associated molecular patterns which in turn result in the 
production of pro inflammatory cytokines resulting in acute inflammation.
[26,27]
 
These chemotherapy induced inflammatory edematous changes ( incited by the 
death of tumour cells) can simulate increase in tumour size on palpation. 
  
MAMMOGRAPHY 
Fiorentino et al concluded that  mammography fared worse than clinical 
examination in predicting residual tumour size.
[19]
 Chagpar et al showed that the 
accuracy of mammography to predict residual tumour size was 70% when 
compared to 75% by ultrasound  and 66% by clinical examination. Sperber et al 
reported that mammography correlated with pathological response only in 50% 
of patients.
[24] 
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 Sun et al have stated that in 53.5% of patients, mammography could not 
identify the change in tumour size following chemotherapy when compared 
with pretreatment assessment and that in patients with  partial response, there 
was no significant reduction in the range of microcalcification.[22] 
The problem with mammography arises mainly in patients with dense 
breasts where the tumour mass cannot be defined sufficiently at baseline for 
future comparisons. Also even in patients with fatty breasts, tumours responding 
to chemotherapy predominantly by the processes of fibrosis or necrosis cannot 
be differentiated from non responding ones as the mammographic density 
remains the same. In a series by Keune et al, of the 144 tumours imaged by 
mammography, size was unable to be defined in 60 (41.7%).
[28] 
Huber et al, in their study, concluded that if the > 50% of the tumour 
margin can be defined at baseline by mammography, final mammographic 
tumour size correlated significantly with the pathological tumour size and 
suggested that for tumours whose margins are ill-defined at baseline, alternative 
imaging modalities should be considered for response assessment.
[29]
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ULTRASONOGAPHY 
Definition of tumour margins are better by ultrasonography when 
compared with mammography except when there is multifocal of ill defined 
tumour. In a study by Keune et al, though ultrasound was able to size 91% of 
tumours initially, it could predict chemotherapeutic response only in 60%.
[28] 
Balu Maestro et al, in a study of 60 tumours, found that ultrasonography could 
correctly predict residual tumour size only in 43% of tumours.
[30] 
Other studies 
have found that ultrasound was not significantly better in than clinical 
examination or mammography.
[19,31] 
In multifocal and illdefined tumors the ability of ultrasound to delineate 
the difference between tumour tissue and normal tissue is less. Moreover when 
the size of the tumour exceeds the size of the probe which is the case in most of 
the patients with LABC, the accuracy of ultrasound in determining tumour size 
is, at best, modest. Fibrosis occurring in the course of response to chemotherapy 
can cause substantial post acoustic shadowing which in turn limits the ability of 
ultrasound to visualise residual tumour mass. 
 
Many studies have reported the superiority of MRI in assessment of 
residual tumour size and multifocality.
[32,33]
 This is possible due to the increased 
contrast resolution inherent to MR imaging. 
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The problem in morphological imaging modalities is that they image only 
the volume of the mass and not the viability of tumour cells. The relationship 
between tumour cells and stroma in an individual tumour is variable as breast 
cancer is very heterogeneous in its biology. Thus tumours that have responded 
well, with the tumour tissue replaced by fibrotic or necrotic mass, may be 
erratically classified as non-responding by morphological imaging. This may 
lead to deprivation of further chemotherapy to which the tumour is sensitive. On 
the other hand, viable tumour cells may remain inspite of resolution of the mass 
resulting in the impression of a responding tumour by morphological imaging. 
This may lead to continuation of ineffective chemotherapeutic regimen when an 
early regimen change or surgery could have helped the patient get adequate 
disease control thus resulting in loss of precious time. 
 
This is where functional imaging is postulated to help. The metabolism of 
tumours has been found to be much more than that of normal tumour tissue. 
Menezes et al have found that breast cancer cells showed an over abundance of 
cytochrome oxidase, an oxidative mitochondrial enzyme, compared to the 
adjacent normal cells. They postulated that the cancer cells induce oxidative 
stress in adjacent normal fibroblasts by making them switch over to anaerobic 
glycolysis which results in the production of large amounts of lactate. This 
lactate is then used up by the cancer cells which retain their ability to metabolise 
lactate through their oxidative mitochondrial enzymes. This hypermetabolism 
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increases the need for vascularity.
[34]
 So metabolism and vascularity can serve 
as markers for the viability of tumour cells. Functional imaging modalities give 
us a reliable idea about the viable tumour burden as they image or measure the 
vascular or metabolic indices. 
 
Vascular imaging modalities aim at the assessment of changes in 
vascularity due to chemotherapy which in turn is dependent on the change in the 
metabolism of cancer cells. Tumour angiogenesis was the term coined by 
Folkman and Hannahan to refer to the induction of angiogenesis in a nascent 
tumour.
[35] 
 
During initial stages of tumour growth, nutrition is derived by diffusion 
of substrates along a concentration gradient. Tumours cannot grow beyond 2-3 
mm unless vascularised as this is the distance limit for diffusion of substrates. 
When a tumour grows beyond this size, there is, inevitably, a zone of hypoxia in 
the centre of the tumour.
[36]
 Hypoxia prevents degradation of Hypoxia inducible 
factor 1α (HIF-1α) which in turn activates the transcription of the genes of pro 
angiogenic proteins like Vascular Endothelial Growth factor (VEGF). These 
proteins are ultimately responsible for recruitment of new vessels – 
angiogenesis.
[37] 
Thus there is an increase in mean vessel density in the tumour 
tissue compared to normal tissue. Thus, in locally advanced cancers of the 
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breast which are invariably large, angiogenesis definitely plays a major role in 
the sustenance of neoplastic cells. 
 
But tumour vessels are abnormal intrinsically. They are dilated, tortuous 
and leaky (increased permeability). Their tunica media is not properly 
developed.
[37]
 So the physiology and physics of blood flow through them are 
very different from normal vessels with flow in the tumour vessels being more 
turbulent and of a low resistance type. 
 
Imaging of vascularity may be direct – imaging the vessels or its 
properties, or indirect - by imaging the uptake or distribution of metabolic 
products which are delivered to the tumour by the vessels, and thereby 
obtaining information about the vessels. 
Direct vascular imaging modalities used at present are Doppler 
ultrasound with or without contrast agent and Dynamic contrast enhanced MRI. 
 
DYNAMIC CONTRAST ENHANCED MRI 
Contrast enhanced MRI employs 2 parameters – Intensity of 
enhancement that reflects the vessel density and rate of wash out which 
reflects the permeability of the tumour vessels. Though MRI does not image 
the tumour vessels directly, signal intensity in contrast enhanced images has 
been shown by Knopp et al to correlate with the vessel density in the 
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tumour.
[38] 
Hulka et al suggested that the measurement of T1 value and 
extraction flow product correlated well with mean vessel density in the 
tumour.
[39]
 Their findings were confirmed by Yeh et al.
[40]
  
 
Many studies have measured the tumour size in the contrast enhanced 
images and compared it with size of the tumour in histopathology not taking 
into account the vascular characteristics (signal intensity or kinetics). 
Kawamura et al studied 11 patients with LABC on primary systemic 
chemotherapy with diffusion weighted and dynamic contrast enhanced MRI 
after each cycle of chemotherapy. They found that tumours that showed 
shrinkage in the area of contrast enhancement after the first cycle of 
chemotherapy showed pathological response. Though they used dynamic 
contrast enhanced MRI, they have not specified the phase in which the 
tumour size was measured.
[41]
 Gilles and co-workers have reported that early 
contrast enhancement detected residual tumour in seventeen out of the 
eighteen patients.
[42]
  Loo et al found that failure of the largest diameter of  
late contrast enhancement to decrease by more than 25% after two cycles of 
chemotherapy had a high specificity for predicting residual tumour at 
histopathology.
[43]
 Abraham et al have reported an accuracy of 97% for MRI 
in predicting pathological residual disease.
[44]
 Yeh et al found a 71% 
correlation between MRI and pathology in assessment of residual tumour, 
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which was far better than clinical examination mammography and 
ultrasound.
[45]
 Similar results were obtained by Rosen et al.
[46] 
  
The main advantage in MRI is its ability to acquire dynamic images and 
compute time intensity curves which can help us image the increase in 
vascular permeability which is an important property of tumour vessels 
differentiating them from normal vessels.
[37] 
 
Knopp et al evaluated the vascular enhancement characteristics of breast 
tumours and compared it with tumour histology, expression of CD-31 (measure 
of vascular density) and VEGR (measure of vascular permeability). They have 
found significant correlation between tissue VEGF expression and vascular 
permeability to contrast agent as measured by the rate constant on MRI. They 
further  suggested that in breast tumours responding to chemotherapy, decrease 
in vascular permeability as evidenced  by the decrease in the rate of contrast 
enhancement, precedes the decrease in vascular density which is reflected by 
the decrease in signal intensity.
[38,47]
  In contrast, studies by Ah see et al and Su 
et al have not found a statistically significant relationship between VEGF 
expression and vascular permeability characteristics on MRI.
[48,49]
 El Khoury et 
al found that there was significant decrease in the washout volume of the 
tumour and Reiber et al found that tumours responding to chemotherapy 
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showed flattening of the time intensity curve after 2 cycles of 
chemotherapy.
[50,51]
   
 
But changes in vascular permeability can be caused even by some 
chemotherapeutic drugs which could then become a confounding factor. Semb 
et al have found that docetaxel causes an increase in vascular permeability 
which leads to an initial increase in fluid filtration followed by plasma protein 
leakage.  
So direct visualisation of vessels seems to be an easier and more 
convincing method of assessment of vascularity especially in follow up of 
proven cases of breast cancer on therapy. This can be done by doppler 
ultrasound. 
 
INDIRECT IMAGING 
MAMMOSCINTIGRAPHY 
It uses technetium labelled MIBI (Methoxy Iso Butyl Isonitrile) to assess 
uptake by the tumour tissue. There are conflicting reports about the value of this 
modality. Mankoff et al in their study found that a decrease of 40% or more in 
the lesion to normal MIBI uptake ratio reliably predicted pathological complete 
response.
[53]
  However, Travaini et al have claimed that pretreatment MIBI 
uptake and washout did not show any significant difference between responders 
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and non responders in their study of 51 patients.
[54]
 The usefulness of 
scintimammography is questionable and the procedure involves exposure to 
ionising radiation as it entails the use of radioactive technetium.  
 
POSITRON EMISSION TOMOGRAPHY 
The uptake of glucose by the tumour has been found to correlate with the 
aggressiveness of the tumour. Mankoff et al have measured the tumour blood 
flow with
 15
O – water and glucose metabolism with 18FDG. They found that 
tumours that did not respond to NACT had significantly increased pre-treatment 
glucose metabolism.
[55]
 In other studies there were conflicting results regarding 
the ability of PET to identify response to chemotherapy.
[56,57,58,59] 
Moreover the increased cost and reduced access to PET facilities 
prohibits its use in our country. 
 
DIFFUSE OPTICAL SPECTROSCOPY 
Diffuse optical spectroscopy (DOS) is now emerging as a non invasive 
indirect imaging modality of tumour metabolism. Pakalniskis et al studied the 
mean tumour haemoglobin levels with DOS and compared them with mean 
vessel density (MVD) of vessels expressing CD-105 and CD31 in the pre-
treatment core biopsy specimen. MVD of CD105-expressing vessels correlated 
significantly with pre-treatment tumour haemoglobin levels in women who 
went on to have pCR and the MVD of CD31-expressing vessels correlated 
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significantly with pre-treatment tumour haemoglobin levels in women who 
went on to have pathological partial response (pPR). This indicates that the pre-
treatment tumour haemoglobin reflects the vascularity of the tumour though the 
biomarkers expressed in the tumour vessels may vary.
[60]
  
In a study by Soliman et al, 10 patients with LABC on PSC were 
followed up with diffuse optical spectroscopy at 1, 4 and 8 weeks after the 
commencement of chemotherapy. They found that percentage values of tumour 
oxygenated haemoglobin, water and scattering power were significantly 
different between responders and non responders as early as 4 weeks after 
starting chemotherapy.
[61] 
Roblyer et al studied 24 tumors under neoadjuvant chemotherapy with 
diffuse optical spectroscopy and found that there was a very significant 
difference in the tumour tissue oxyhemoglobin between responders and non 
responders and the difference was maximum just one day after starting 
chemotherapy.
[62] 
Cerussi et al showed in their study that Tissue optical index measurement 
of the tumours was able to differentiate between pCR and non –pCR tumours at 
the midpoint of therapy regardless of drug or dosing strategy. The difference 
was statistically significant.
[63]
 In another study by the same authors which 
included 11 patients, they found that 1 week posttreatment tissue 
deoxyhemogobin concentration had 83% sensitivity and 100% specificity for 
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predicting therapeutic response while combined tissue deoxyhemogobin 
concentration and tissue water changes had 100% sensitivity and specificity 
We see that different parameters were found significant in each of these 
studies. The technique of diffuse optical spectroscopy for purposes of medical 
imaging has not been standardised. In addition, special equipment is required 
for such studies along with optical compensation media whose accessibility and 
affordability are under question in a developing country like ours. 
DOPPLER ULTRASOUND 
Doppler ultrasound gives us an avenue to image the tumour vessels 
directly. The quantitative assessment is done by colour or power doppler. The 
assessment of flow characteristics in the tumoral vessels is done using spectral 
doppler. 
Kedar et al concluded that the change in tumour vascularity as seen on 
colour doppler was able to predict the response to chemotherapy at least 4 
weeks earlier than clinical examination and B mode ultrasound in 40% of 
patients.
[65] 
Huber et al have conducted a semiquantitative analysis of the detectable 
vessel density within the tumour tissue using colour Doppler. They have used a 
computer aided software to compute the colour pixel density (percentage of the 
pixels within the ROI occupied by colour) with a manually drawn ROI and 
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found that the agreement between the change in colour pixel density and 
histopathological response was substantial.
[66] 
Vallone et al have compared colour doppler and contrast enhanced colour 
doppler in identifying responders among 50 LABC patients on NAC. They have 
reported that in 9 cases conventional Doppler failed to detect tumor vascularity 
where as contrast enhanced doppler did. These cases were histologically proven 
to have residual disease. They concluded that contrast enhanced doppler was a 
more sensitive method to detect tumour vascularity and thereby residual tumour 
tissue.
[67] 
Kuo et al have quantified tumour vascularity using power doppler and 
computing vascularity index which is the ratio of number of pixels with colour 
to the total number of pixels within the ROI. They evaluated the patients on day 
0, day 1 and day 8 of chemotherapy and found that vascularity index increased 
initially before decreasing when compared to the baseline. They found all 
patients with an initial increment in VI of >5% was found to respond to 
chemotherapy and that the change in VI predated the change in tumour size as 
assessed by clinical examination and B mode ultrasonography. Though they had 
used a software programme to calculate the vascularity index, they are of the 
opinion that a vascularity change of 5% could easily be detected by an 
experienced sonographer even without the assistance of computational 
software.
[68] 
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There are two hypotheses regarding vascular resistance in tumour vessels. 
The presence of perfusion shortcuts due to the presence of arteriovenous shunts 
and the lack of vasomotor control due to the absence of muscle layer (tunica 
media) in the tumour vessels result in a low resistance flow. On the other hand 
increased vascular permeability results in leakage and accumulation of 
osmotically active substances in the interstitium giving rise to increased 
interstitial pressure which causes a high resistance to blood flow (viscous 
resistance). The counterbalancing effects both these factors could be expected to 
play a role in tumors and the so ultimate flow resistance has been found to be 
different in different areas within the same tumour.
[70] 
Kumar et al have studied 50 cases of locally advanced breast cancer with 
colour doppler twice during their treatment regime -  at diagnosis and after three 
cycles of chemotherapy with CAF regimen. They put forth a colour doppler 
scoring system taking into account PSV, RI and PI to predict the pathological 
response giving each a score of 1,2,3 or 4 when there was a change of <25%, 25 
– 50%, 50 – 75% or >75% from the baseline. They concluded that a cumulative 
Doppler score of >5 had a sensitivity of 91.7%. They also found that the 
complete disappearance of flow signals was highly specific for the prediction of 
complete responders.
[71] 
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Singh et al have showed that tumours showing an increase in  peak 
systolic velocity while on treatment had a greater likelihood of  recurrence and 
that a decrease in peak systolic velocity correlated well with clinical response. 
The RI and PI did not show any consistent trend in their study.
[72] 
Osanai et al have found that lowest resistivity index of the tumour vessels 
shows significant correlation with tumour grade and Nottingham prognostic 
index. Nottingham prognostic index which is used to predict patient survival 
takes into account tumour size, nodal stage at presentation and histological 
grade.
[73] 
Several studies have shown that a higher RI was indicative of malignancy 
among breast masses. 
[74,75,76] 
In a series of cases, Oksuzoglu et al have reported 
that during the course of chemotherapy, the RI of the tumours that responded to 
chemotherapy decreased significantly (p value = 0.04). They also found that the 
decrease in RI was proportional to the decrease in size of the tumour.
[77] 
In a study on 49 cases of carcinoma of endometrium, Lee et al have found 
that RI values correlated significantly not only with histological grade and 
lymphovascular invasion but also with microvessel density and vascular 
endothelial growth factor (VEGF) levels.
[78] 
37 
 
Greco et al  studied the usefulness of colour doppler indices in 14 patients 
undergoing neoadjuvant chemotherapy for locally advanced carcinoma of the 
cervix. They reported a significant increase in RI and PI of both in the cervical 
artery and in the intratumoral vessels. The cervical arterial RI and PI were 
significantly less than that of healthy controls.
[79] 
In 2003, Alcazar et al conducted a study in 21 patients with locally 
advanced cervical cancer and found that the initial lowest RI, lowest PI and 
highest PSV of the intratumoral vessels had a significant correlation with final 
clinical response assessed at the end of concurrent chemoradiotherapy. As the 
patients did not undergo surgery, the results could not be compared with 
pathological response.
[80] 
Kerimoglu et al have compared colour Doppler ultrasound with dynamic 
contrast enhanced MRI for the prediction of response to radiotherapy to locally 
advanced cervical cancer. 13 cases underwent transvaginal ultrasound with 
colour and spectral Doppler examination 6 months before and 6 months after 
radiotherapy.  14 healthy controls also underwent transvaginal ultrasound with 
colour doppler for comparison. It was found that the RI of the cervical vessels 
was significantly lower in patients with cancer when compared to the controls. 
They found that in 10 out of the 11 patients who showed response to therapy, 
the post treatment RI showed a significant increase when compared with the 
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pretreatment RI. They also found a 100% correlation between MRI and RI for 
assessment of response to therapy.
[81]
 
 
Jurado et al compared the lowest intratumoral PI measured by TVUS 
before surgery with the histological response. They found a significant 
association between the lowest PI and lymph node involvement, depth stromal 
invasion and lymphovascular invasion which are important predictors of 
survival. Using the cut off lowest PI <0.82 they were able to predict the need for 
further treatment after surgery.
[82] 
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STUDY 
AIMS AND OBJECTIVES 
1. To evaluate Doppler ultrasound parameters in assessment of vascular 
response to chemotherapy in patients with locally advanced breast cancer 
and to compare it with morphological response by clinical examination 
and ultrasound taking post-surgical histopathological response as gold 
standard 
2. To ascertain the ability of Doppler ultrasound to predict the response 
early during the course of chemotherapy. 
 
MATERIAL AND METHODS 
This was a prospective study conducted in madras medical college. 
Informed written consent was obtained from all patients prior to the start of the 
study. Institutional Ethics committee approval was obtained prior to the start of 
the study 
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INCLUSION CRITERIA 
1. Female patients of 17 to 70 years of age with  locally advanced 
breast cancer as per AJCC TNM staging (7
th
 edition) 
2. Presence of histological proof of malignancy  
3. Inoperability of the lesion at presentation 
4. No clinical or radiological evidence of metastasis  
5. No history of prior treatment for any malignancy 
6. Fit for chemotherapy with anthracycline based regimen 
 ECOG performance status 0-2 
 Normal cardiac function (Echocardiographic ejection fraction 
>50%) 
 Normal renal and liver function tests 
 No other co morbid illness which precludes chemotherapy 
EXCLUSION CRITERIA 
1. Pregnant patients 
2. Metastatic breast cancer 
3. Patients unfit for chemotherapy 
4. ECOG performance status >2 
5. History of treatment for prior malignancy 
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METHODS: 
All patients who fulfilled the inclusion criteria were subjected to a 
complete clinical examination of the breast, axilla and other major organ 
systems. Clinical examination of the breast entailed measurement of the breast 
mass in 2 perpendicular directions using vernier calipers, documentation of the 
surface, consistency, mobility, skin or chest wall invasion. The contralateral 
breast was also palpated for the presence of mass lesion. Both axillae were 
palpated for nodes and if present, their number, size and mobility were noted. 
Both supraclavicular fossae were palpated for the presence of nodes. Patients 
were then examined for clinical signs of metastases as evidenced by 
hepatomegaly, jaundice, ascites, pulmonary or neurological symptoms or signs 
and bone pain. The patients then underwent metastatic work up with 
ultrasonograms of the abdomen, CT scans of chest and abdomen and bone scan 
for staging. 
Then the patients underwent a comprehensive breast ultrasound with 
colour and spectral Doppler in Esoate My Lab 60 ultrasound machine using 
high frequency probe (7 – 13 MHz). 
In the ultrasound examination, the exact location of the lesion along with 
the measurements in the three dimensions are noted which enables us to 
calculate the volume of the tumor in cubic cm using the formula for calculation 
of volume of an ellipsoid as  
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Volume in cm
3
 = d₁ x d₂ x d₃ x ∏/6 
In the colour Doppler examination, the pulse repetition frequency was 
kept as low as possible to pick up even very slow flowing vessels. The wall 
filter was lowered to the maximum possible extent, such that it was just enough 
to avoid artefacts. The dynamic range was kept at 60. The optimal settings were 
selected for each patient individually at the baseline examination and the same 
settings were used in all further sequential examinations of a given tumour. 
Thus each patient acted as her own control. Then the number of colour signals 
noted within a standard colour box of area 1cm
2
completely filled with tumour 
was counted visually and recorded.  
Then the spectral Doppler was switched on and the spectra were obtained 
in a portion of the vessel that is relatively straight. Care was taken to ensure that 
the waveforms obtained were continuous. The peak systolic velocity PSV, end 
diastolic velocity EDV and the resistivity index RI were measured. A minimum 
of three values were obtained. The lowest RI was taken for analysis. 
Then the axilla was examined for lymph nodes and any abnormal node 
looking node (ie., those with round shape, loss of fatty hilum, diffuse or 
eccentric cortical thickening or ill defined margins) was noted. 
43 
 
CHEMOTHERAPY 
All patients received 4 cycles of preoperative FAC chemotherapy once in 
21 days as follows: 
1. Inj. Cyclophosphamide 500 mg/m2 intravenously on day 1 
2. Inj. Doxorubicin 50 mg/m2 intravenously on day1 
3. Inj. 5-Fluorouracil 500mg/m2 intravenously on day 1 
Clinical examination, ultrasonography and Doppler examination 
were done at diagnosis before starting chemotherapy and repeated before 
every cycle of chemotherapy. At the end of four cycles of chemotherapy, 
a final clinical, sonographic and vascular response was recorded for every 
patient. 
A scoring system based on the modified Response Evaluation 
Criteria In Solid Tumours (RECIST) v1.1 was employed for assessment 
of morphological response by clinical and sonographic evaluation 
depending on the change in tumour size from baseline as shown in table 
1.
[83] 
Both Progressive disease and stable disease according to RECIST 
were combined into the category of no response. 
For Doppler, a scoring system modified from the one put forth by 
Kumar et al was used taking the RI and number of flow signals into 
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account. PSV was not included in our scoring system which is shown in table 2. 
 
Table 1: Scoring system for clinical and sonographically assessed 
response (based on RECIST criteria version 1.1) 
Score Response 
% change from baseline (for clinical 
assessment- size of tumour, for sonography- 
volume of tumour) 
1 No response 
(NR) 
Any increase or no change or a decrease of 
<30%in size/volume of tumour, 
2 Partial 
response (PR) 
Decrease of >30% in size/volume of tumour 
3 Complete 
response(CR) 
No clinically palpable tumour or 
sonographically detectable tumour at the end 
of chemotherapy 
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Table 2: Scoring system for Doppler assessment of response 
(modified from the scoring system proposed by Kumar et al) 
SCORE DEFINITION OF RESPONSE (RI) 
1     Any decrease, no change or <25% increase in RI 
2     25-50% increase in RI 
3     50 - 75% increase in RI 
4 >75% increase in RI or complete disappearance of flow 
signals 
SCORE DEFINITION OF RESPONSE (number of 
signals/vessels) 
1 Any increase, no change or <25% decrease in feeder 
vessels 
2     25-50% decrease in feeder vessels 
3     >50% decrease in feeder vessels 
4     Complete disappearance of flow signals 
 
The scores obtained separately for RI and the number of flow 
signals at the end of chemotherapy were added to get a cumulative 
response assessment score by doppler as shown in table 3. 
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Table 3 : Cumulative Doppler Score 
CUMULATIVE 
SCORE 
RESPONSE 
2-3 No change/increase in vascularity (no response) 
4-6 Partial decrease in vascularity (partial response) 
7-8 Complete disappearance of vascularity (complete 
response) 
 
All patients underwent modified radical mastectomy (MRM) after 
completion of four cycles of chemotherapy and post operative tumour specimen 
was assessed for size, grade, lympho-vascular invasion and lymph nodal status. 
Final response to chemotherapy was documented as a percentage of change in 
tumour from baseline using the RECIST criteria. 
The results obtained were tabulated in an Excel format. The response 
assessments on the basis of clinical examination, ultrasonography and Colour 
Doppler were compared with the histological response as gold standard and the 
assessment method correlating best with histopathology was analyzed using 
weighted kappa statistics, t tests and chi square tests with the help of the SPSS 
version 20 statistical software. A „p‟ value of <0.05 was considered as 
significant. 
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RESULTS & STATISTICAL ANALYSIS 
Out of 182 patients newly diagnosed with breast cancer during the study 
period, 63 patients had LABC, which is 34.6% of all breast cancers in our 
hospital during the period. Fifty four patients were eligible to enter the study as 
they satisfied the inclusion criteria. The other 9 patients were excluded as; 2 
patients was not willing to undergo any treatment,  one patient had rheumatic 
heart disease and was in failure with ejection fraction of <50%, 1 patient had 
grossly elevated renal parameters,  two patients were aged above 75 years with 
performance status >2, and three patients were lost to follow up during 
chemotherapy.  
The mean age of our patients was 50.9+ 8.3 years with a range of  27-65 
years. 44% of patients were over 50 years (no. of patients=24) and one patient 
was below 30 years (2%). The results are shown in the table 4. 
Table 4 : Age distribution of patients 
Age (years) No. of patients Percentage 
<30 1 2 
30 – 50 29 54 
>50 24 44 
Total 54 100 
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47 patients (87%) were in tumour stage T4. Of these, Skin involvement 
alone (T4B) was seen in 45 patients (83%). Two patients had both skin and 
chest wall involvement (T4C) (4%). Seven patients (13%) had neither skin 
nor chest wall involvement and were in tumour stage T3. The tumour stage 
distribution at presentation is shown in table 5. 
Majority (76%) of our patients presented with  stage IIIB. Twenty 
percent of patients (11 patients) presented in stage IIIC. Two patients (4%) 
presented with stage IIIA. The tumour was in the right breast in 22 patients 
(40.3%) and in left breast in 32 patients (59.7%). The results are shown in 
table 6. 
Table 5 : Tumour stage at presentation 
Tumour stage No. of patients Percentage 
T3 6 11 
T4B 45 83 
T4C 2 4 
T4D 1 2 
Total 54 100 
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Table 6 : TNM Stage at presentation 
TNM stage No. of patients Percentage 
IIIA 2 3.7 
IIIB 41 75.9 
IIIC 11 20.4 
Total 54 100 
 
 In 28 patients (52%),at diagnosis, the nodal status was N1. 14 
patients(26%) had N2 and 11 patients(20%) had N3. Only one patient had 
clinically node negative axilla, N0 disease (2%). The results are shown in 
table 7. 
Table 7 : Nodal status at presentation. 
Nodal status No. of patients Percentage 
N0 1 2 
N1 28 52 
N2 14 26 
N3 11 20 
Total 54 100 
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The mean tumour size at diagnosis was 8.9 + 3.2 cm. 34 patients (62.9%) 
had a tumour size of 5-10 cm. Thirteen patients had a tumour size of more than 
ten centimetres at diagnosis (24.1%) and 7 patients had a tumour size of less 
than 5 cm (13%).  The tumour size at baseline is shown in table 8. 
On B mode ultra sonogram, the mean volume of tumour was 106.3+ 46.7 
cc. At diagnosis, 8 patients had a tumour volume of over 150 cc (24.1%) 
whereas 13 patients had tumour volume of <75 cc (1.9%). Thirty three patients 
had a tumour volume of 75 - 150 cc (14.8%) at diagnosis. The tumour volume 
at diagnosis is shown in table 9. 
Table 8: Tumour size at baseline (clinical examination) 
TUMOR SIZE Number of patients Percentage 
<5 cm 7 13 
5-10 cm 34 62.9 
>10 cm 13 24.1 
TOTAL 54 100 
Mean + SD 8.9 + 3.2 (cms) 
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Table 9 : Tumour volume at baseline 
Tumour volume by 
USG at baseline 
Number of patients Percentage 
<75cc 13 24.1 
75– 150 cc 33 61.1 
>150 cc 8 14.8 
TOTAL 54 100 
Mean volume 106.3 ± 46.7 cc 
 
53 patients (98%) had infiltrating ductal carcinoma (not otherwise 
specified type). According to literature also, this is the most common 
histological subtype of breast cancer. One patient had infiltrating ductal 
carcinoma with neuroendocrine differentiation (2%). 
Scarf-Bloom-Richardson score was used to calculate the grade of the 
tumour. Tumours of grade 2 were seen in 26 patients (48.1%), tumours of grade 
1 in 16 patients (29.6%) and  tumours of grade 3 in 12 patients (22.3%). This is 
shown in table 10. 
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Table 10: Tumour grade distribution 
TUMOUR GRADE Number of patients Percentage 
Grade 1 16 29.6 
Grade 2 26 48.1 
Grade 3 12 22.3 
TOTAL 54 100 
 
The estrogen and progesterone receptor status as well as Her-2/neustatus 
were assessed from the histological sample. 37 patients (70%) were positive for 
ER/PgR and 15 patients (28%) showed Her-2 positivity which included both 
ER/PgR positive and ER/PgR negative tumours. All 3 markers were negative 
(Triple negative pattern) was seen in 12 patients (22.2%). The receptor status in 
the study group is shown in table 11. 
Table 11 : Receptor status in the study group 
RECEPTOR STATUS N % 
ER and/orPgR +, Her-2/neu- 27 50.7 
ER and/orPgR+, Her-2/neu + 10 18.2 
ER-, PgR-, Her-2/neu + 5 8.9 
ER-, PgR-, Her-2/neu – 12 22.2 
Total 54 100 
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DOPPLER FEATURES:  
A baseline doppler examination of the tumour was done at diagnosis and 
was repeated after each cycle. Majority of the tumours were hypervascular( >5 
vessels within 1 cm
2 
of the tumour). There was no predominant vascular pattern 
as most tumours had both central and peripheral vascularity.  
The most striking feature of the intratumoral vessels was their tortuosity. 
Their course was marked with multiple sharp turns. This was important because 
it posed significant difficulty in correction of doppler angle when a doppler 
spectrum was to be obtained. Though care was taken to obtain all values from 
relatively straight portions of the vessels and angle correction was done to the 
best possible extent, the accuracy of doppler angle dependent velocity indices 
could not be assured owing to the extreme tortuosity. The values of the velocity 
indices showed a wide variation evidenced by the higher value of standard 
deviation relative to the mean. 
Table 12 : Doppler findings 
 Mean value at baseline Mean value after cycle 4 
PSV(cm/sec) 32.6+16.9 18 + 16.3 
EDV 14.2 ± 16.2 4.7 ± 6.6 
RI 0.61 + 0.14 0.64+ 0.29 
 NUMBER OF SIGNALS 7.2+ 2.2 1.6+1.5 
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The Doppler values (PSV, EDV, RI and number of flow signals) were 
tabulated at baseline and after every cycle of chemotherapy. The mean RI at 
baseline was 0.61 + 0.14 which increased to 0.64+ 0.29 after four cycles. The 
number of flow signals decreased from 7.2 + 2.2 at baseline to 1.6 + 1.5 at the 
end of chemotherapy. 
The mean PSV measured at baseline was 32.6 + 16.9 cm/sec, and at the 
end of four cycles it was 18 + 16.3 cm/sec.  The mean EDV at baseline was 14.2 
± 16.2 cm/sec  which showed decrease to 4.7 ± 6.6cm/secafter 4 cycles of 
chemotherapy. 
Table 13 : Change in doppler indices after chemotherapy 
 PSV EDV RI Vessels 
 N % N % N % N % 
No change 0 0 1 1.8 2 3.7 2 3.7 
Increase 12 22.2 11 20.3 33 61.1 3 5.6 
Decrease 42 77.8 42 77.8 19 35.2 49 90.7 
Total 54 100 54 100 54 100 54 100 
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The changes in value of Doppler indices obtained at the end of 
chemotherapy were tabulated. An increase in RI was observed in 33 patients 
(61.1%) whereas 19 patients (35.2%) showed a decrease with chemotherapy. 
Two patients had no change in RI at the end of four cycles of chemotherapy. 
Compared to the baseline, the number of flow signals decreased in 49 patients 
(90%), increased in three patients (5.6%) and remained the same in 2 patients 
(3.7%). Forty two patients (77.8%) had a decrease in PSV and 12 patients 
(22.2%) had an increase. In 11 patients (20.3%) there was an increase in EDV 
and in 42 patients (77.8%) there was a decrease. One patient had no change in 
EDV at the end of therapy. The results are shown in table 13. 
At the end of chemotherapy, 19 patients (35.2%) showed an RI score of 1 
(<25% increase from baseline), 14 patients (25.9%) showed a score of 2 (25 to 
50% increase from baseline), 12 patients(22.2%) showed a score of  3 (50 to 
75% increase from baseline) and 9 patients (16.6%) showed a score of 4(>75% 
increase from baseline). 72% of patients showed >75% decrease in the number 
of flow signals at the end of chemotherapy (score = 3), whereas only 11% 
patients showed a complete disappearance of flow signals. 
The cumulative Doppler score at the end of therapy was between 2-3 in 8 
patients (14.8%), between 4-6 in 37 patients (68.5%) and 7-8 in 9 patients 
(16.7%). 
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HISTOPATHOLOGICAL FINDINGS 
The post operative specimen was examined histopathologically and the 
results were tabulated. Eight patients (14.8%) showed pathological complete 
response in the primary tumour and 29.6% achieved nodal complete response. 
Nine patients showed no response to chemotherapy (16.7%). Combined 
response (both complete and partial response) rate was 83.3%. 
 Tumour size in the resected specimen was <2 cm in 20 patients (35%), 2 
to 5 cm in 21 patients (42.1%), and >5 cm in five patients (9%). 39 patients 
(72.2%) showed lymphovascular invasion. Out of the 47 patients who had skin 
involvement at diagnosis, 44 patients (93.6%) showed resolution of skin 
invasion  post chemotherapy. Chest wall involvement had resolved in both the 
patients who had chest wall involvement at diagnosis. The results are shown in 
table 14. 
Post operative nodal status was N0 in 16 patients (29.6%), N1a in 26 
patients (48.1%), N2a in 11patients (20.4%) and N3a in 1 patient (1.9%).  
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Table 14 :Histopathological findings 
 N % 
Tumour size: 
0 cm 
<2 cm 
2-5 cm 
>5 cm 
 
8 
20 
21 
5 
 
14.8 
37 
38.9 
9.3 
Lymphovascular 
invasion 
39 72.2 
Skin involvement 3 5.5 
Axillary lymph nodes 
0 nodes 
<3 nodes 
3-6 nodes 
>7nodes 
 
16 
26 
11 
1 
 
29.6 
48.1 
20.4 
1.9 
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The pre-treatment clinical characteristics of the cases were analysed 
with respect to histopathological response. The results are shown in table 15. 
 
Table 15: Pre-treatment clinical characteristics versus histological 
response 
 
HISTOPATHOLOGICAL RESPONSE 
P value 
RESPONDERS 
(CR AND PR) 
NONRESPONDERS 
(NR) 
Age: 
<50 years 
>50 years 
 
20 
25 
 
5 
4 
 
0.807 
Tumour size: 
<5 cm 
5-10 cm 
>10 cm 
 
3 
32 
10 
 
4 
2 
3 
 
 
0.003 
Tumour grade: 
Grade 1 
Grade 2 
Grade 3 
 
13 
21 
11 
 
3 
5 
1 
 
 
0.67 
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In our study, the only clinical factor which correlated significantly with 
histological response was tumour size at baseline. Medium sized tumours of 5-
10 cm had a significantly better response rate than tumours <5cm or >10 cm 
(p<0.003). Age of the patient, tumour grade and nodal status at presentation did 
not correlate with histological response.  
The pre treatment volume of the tumour was compared with pathological 
response and the results were tabulated in the table 16. Tumours with a baseline 
volume between 75 and 150 cc had a better response rate than those with a 
volume less than 75cc or more than 150cc.  
The baseline Doppler characteristics were compared with 
histopathological response as shown in table 17.  
 
Table 16 :Pre treatment tumour volume versus histopathological 
response 
Tumour volume 
by USG at 
baseline 
NON 
RESPONDERS 
RESPONDERS P value 
<75cc 5 8 
 
0.02 
75– 150 cc 2 31 
>150 cc 2 6 
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Table 17: Pre-treatment Doppler characteristics versus histological 
response: mean values 
 Responders Non responders p value 
Mean  baseline PSV 31.9+ 16.5 35.6+ 19.8 0.55 
Mean baseline EDV 22.2 ± 18.7 31.9± 32.7 0.22 
Mean baseline RI 0.59 + 0.14 0.70+ 0.09 0.028 
Mean number of 
feeder vessels at 
baseline 
7.7 + 2 4.7+ 1.5 <0.0001 
 
It was observed that the mean number of feeder vessels was significantly 
lower in tumours which did not respond to chemotherapy (4.7+ 1.5) compared 
to tumours which responded well to chemotherapy (7. 7 + 2). The baseline 
mean RI was also found to be significant with tumours having a lower pre-
treatment RI showing better response (p=0.039). The baseline mean PSV and 
EDV values were not significantly different between responders and non 
responders. 
 
61 
 
Table 18: Baseline RI and feeder vessels versus response: absolute values 
 
HISTOLOGICAL RESPONSE  
P VALUE NON RESPONDERS RESPONDERS 
RI 
<0.5 
0.51-0.70 
>0.70 
 
0 
5 
4 
 
10 
27 
8 
 
 
0.109 
Total 9 45  
Vessels 
<5 
6-8 
>8 
Non Responders 
7 
1 
1 
Responders 
6 
13 
26 
 
 
0.0002 
Total 9 45  
 
The number of signals observed at baseline was very significantly 
different, with tumours having fewer than five feeder vessels having a tendency 
for non responsiveness to chemotherapy (p=0.0002). The absolute baseline RI 
values also showed significant difference between responders and non 
responders (p=0.03). The baseline PSV and EDV did not correlate with 
response (p=0.231).  
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The grade of the tumour determined by the Scarf Bloom Richardson 
scoring system was compared with the baseline RI values. The baseline RI 
values had a good correlation with the tumour grade, with grade 1 tumours 
having a higher RI than the grade 3 tumours. An RI cut off of 0.70 had a good 
predictive value (83%) for grade 1 tumours.  The correlation was statistically 
significant (p<0.00001). But both baseline RI and grade of the tumour did not 
show any significant correlation with histological response. The results are 
shown in table 19. 
Table 19: Baseline RI score versus grade of tumour 
 GRADE 1 GRADE 2 GRADE 3 TOTAL 
<0.50 0 3 9 12 
0.51-0.70 6 22 2 30 
>0.70 10 1 1 12 
TOTAL 16 26 12 54 
P VALUE = <0.0001 
 
We found that the change in RI after 4 cycles of chemotherapy 
correlated significantly with histological response, with a higher number of 
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non responders having an RI score of 1 (<25% increase from baseline). The 
results were statistically significant (p<0.0001) and are tabulated in table 20. 
Table 20: RI score versus histological response 
RI score at end of 
chemotherapy 
Histopathological response P value 
 NR PR CR Total 
 
 
<0.0001 
1 7 12 0 19 
2 2 10 2 14 
3 0 12 0 12 
4 0 3 6 9 
Total 9 35 8 54 
 
COMPARISON OF RESPONSE 
Clinical, sonographic, vascular and pathological response for patients 
were tabulated and compared. 8 patients achieved pathological complete 
response which is the gold standard. Complete response was seen in 21 patients 
as per clinical assessment, 8 patients in ultrasound assessment and 9 patients as 
per doppler assessment The results are shown in table 21. 
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Table 21: Comparison of clinical, sonographic, vascular and histological 
response 
RESPONSE 
Clinical 
response 
Sonographic 
response 
Vascular  
response 
Pathological 
response 
N % N % N % N % 
NR 9 16.6 12 22.2 8 14.8 9 16.7 
PR 24 44.4 34 63 37 68.5 37 68.5 
CR 21 36.8 8 14.8 9 16.7 8 14.8 
TOTAL 54 100 54 100 54 100 54 100 
 
Sixteen percent (n=9) of patients had no response according to clinical 
assessment whereas 23% (n=13) according to ultrasound and doppler 
assessment and 18% (n=10) according to histological assessment had no 
response. 
Response assessed by clinical, sonographic and Doppler methods was 
compared compared with the gold standard of pathological response 
individually.  
The clinical and histological responses are compared in table 22. Only 
seven patients out of 21 who had CR by clinical examination, had pathological 
CR. Of the remaining, 12 had only PR and 2 had NR on HPE. Of the 10 patients 
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who had NR on clinical assessment, 6 patients had  NR and 4 patients had PR 
on HPE. Out of the 26 patients who had  PR on clinical examination, 23 had PR 
on HPE also; 1 patient had CR and 2 patients had NR on HPE.  
Table 22: Clinical response versus histological response 
CLINICAL 
RESPONSE 
HISTOLOGICAL RESPONSE 
TOTAL 
NR PR CR 
NR 5 4 0 9 
PR 2 21 1 24 
CR 2 12 7 21 
TOTAL 9 37 8 54 
 
The ultrasound and histological responses are compared in table 23. Out 
of nine patients who had CR as per sonographic assessment, three patients 
(37.5%) had CR, four patients had PR and one patient had NR on HPE. Five 
patients (62.5%) who had pathological complete response were found to have 
partial response by sonographic assessment. This may be due to the presence of 
fibrotic mass after chemotherapy which is taken as residual tumour mass at 
ultrasound but contains no viable tumour cells on histological examination. 
Eight out of the thirteen patients who had no response on sonography had no 
response in HPE and the remaining 5 had partial response. Out of the 36 
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patients who had PR on sonographic assessment, 30 patients had PR on HPE 
also.  
Table 23: Sonographic response versus histological response 
SONOGRAPHIC 
RESPONSE 
HISTOLOGICAL RESPONSE 
TOTAL 
NR PR CR 
NR 7 5 0 12 
PR 1 28 5 34 
CR 1 4 3 8 
TOTAL 9 37 8 54 
 
The doppler and histological responses are compared in table 24. We 
found that, of the 9 patients who had CR on Doppler assessment, six patients 
had CR and three patients had PR on histological assessment. Eight (88.9%). 
Out of the 9 patients who had no response in Doppler assessment, had no 
response on HPE also.  
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Table 24: Vascular response versus histological response 
VASCULAR  
RESPONSE 
HISTOLOGICAL RESPONSE  
NR PR CR TOTAL 
NR 7 1 0 8 
PR 2 33 2 37 
CR 0 3 6 9 
TOTAL 9 37 8 57 
 
The sensitivity, specificity and predictive values of various modalities for 
predicting a response on histology at the end of therapy was calculated. We 
found that although clinical examination had the highest sensitivity (87.5%) for 
predicting CR, it had a lower specificity (71.4%) than B mode ultrasound 
(89.8%) or Doppler (93.8%). Both clinical examination and Doppler had a very 
high negative predictive value for prediction of CR (97.2% and 95.8% 
respectively). It was also observed that the positive predictive values of clinical 
examination and sonography were low (33.3% and 37.5% respectively) 
compared to Doppler (66.6%). The results are shown in table 25.   
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Table 25: Sensitivity and Specificity of the modalities for predicting a 
pathological CR. 
 Sensitivity Specificity PPV NPV 
Clinical examination 87.5% 69.5% 33.3% 97% 
Sonography 37.5% 89.1% 37.5% 89.1% 
Doppler 80% 93.4% 66.7% 95.6% 
 
 
The sensitivity, specificity and predictive values for the various modalities 
for prediction of lack of response on histopathology were calculated and the 
results were tabulated in table 26. Doppler had a very high specificity and 
positive predictive value (97.8% & 88.9%) compared to clinical examination 
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(91.4% & 60%) and B mode ultrasound (89.3% & 61.5%). The sensitivity and 
NPV of Doppler was almost equal to that of B mode ultrasound. 
 
Table 26 : Sensitivity and specificity of the modalities for predicting non 
responders on histopathology 
 Sensitivity Specificity PPV NPV 
Clinical examination 55.6% 91.1% 55.6% 91.1% 
Sonography 77.8% 88.9% 58.3% 95.2% 
Doppler 77.8% 97.8% 87.5% 95.6% 
 
A cumulative Doppler score of >3 after completion of chemotherapeutic 
regimen had a high sensitivity (90%), specificity (90%) and positive predictive 
value (98%) for prediction of response (both CR and PR). Similarly, a 
cumulative Doppler score of >6 was highly predictive of pathological complete 
response. 
The accuracy of prediction of response was compared for all three 
modalities in table 27. The accuracy of response prediction was 61.1% for 
clinical examination, 70.3% for ultrasound and 85.1% for Doppler. 
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Table 27 : Accuracy of response prediction. 
 
No. of  correctly 
predicted non 
responders 
No. of correctly 
predicted partial 
responders 
No. of correctly 
predicted 
complete 
responders 
Clinical 
examination 
5 21 7 
Ultrasound 7 28 3 
Doppler 7 33 6 
 
 
Total number of 
accurate results 
Total number of 
patients 
 
Accuracy 
Clinical 
examination 
33 54 61.1% 
Ultrasound 38 54 70.3% 
Doppler 46 54 85.1% 
0
20
40
60
80
100
Accuracy 
Accuracy
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AGREEMENT – WEIGHTED KAPPA STATISTICS 
Using weighted kappa statistics, agreement between the response 
obtained by clinical, sonographic and vascular assessment and pathological 
assessment was calculated and results were tabulated. It was found that the 
agreement between vascular and histological response was the best of the lot (ĸ 
=0.71). Agreement between clinical and histological response was the least (ĸ 
=0.39). The agreement between ultrasound response and pathological response 
was intermediate (ĸ=0.48). The agreement was rated as fair, moderate or good, 
according to the definition of the kappa agreement statistics.  
 
Table 28: Agreement between clinical, sonographic, vascular response 
and pathological response (weighted kappa statistics) 
 K (95% CI) P value Agreement 
HPE and clinical 
response 
0.39 
(0.19-0.58) 
<0.0001 FAIR 
HPE and sonographic 
response 
0.48 
(0.23-0.73) 
<0.0001 MODERATE 
HPE and vascular 
response 
0.77  
(0.60-0.92) 
<0.0001 GOOD 
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Prediction of non responders to chemotherapy was done at interim 
assessment (after the completion of two cycles of chemotherapy), using a 
criterion of failure to achieve at least a 25% expected change from baseline. The 
results are summarized in table 29. 
Table 29: Prediction of non responders after 2
nd
 cycle chemotherapy 
using 25% change from baseline as cut off 
 SENSITIVITY SPECIFICITY PPV NPV 
Clinical 55.6% 82.2% 38.5% 90.2% 
USG 66.7% 86.7% 50% 92.8% 
RI 90% 84.4% 53.3% 97.4% 
Feeder 
vessels 
66.7% 93.3% 66.7% 93.3% 
0
20
40
60
80
100 Clinical 
examination
Ultrasound
No. of vessels
RI
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The change in RI had high sensitivity and specificity for predicting non 
responders (90% and 91.4% respectively) with a high negative predictive value 
(98%). Failure of the vascular signals to decrease by 25% after two cycles also 
had a high specificity and sensitivity (70% and 95% respectively) for predicting 
non responders with a negative predictive value of 94%. Clinical examination 
and sonography also had high negative predictive values but their sensitivity 
and specificity values were low when compared to those of Doppler. The 
accuracy of prediction was good for Doppler with 79%. 
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DISCUSSION 
The incidence of LABC in our hospital which is a tertiary care centre is 
34.6%. This is concordant with the incidence levels in developing countries (30 
– 60%).[83] There was no significant difference in the response rates of  women 
below 45 years of age as against those above 45 years. The tumour size and 
receptor status showed a varied pattern without any predominant pattern. 
The ER/PgR positivity rate was 68% which was comparable to those in 
western countries.
[83] 
The triple receptor negative subset constituted 22.2% 
which concurred with the world figures (15 – 25%).  
The overall response rate was 83.3%.This is in concordant with many 
studies whish have reported response rates of 85 – 90% to primary systemic 
chemotherapy especially with anthracycline based regimen like our study. The 
rate of pathological complete response is 14.8%. 
Nine patients (16%) did not respond to chemotherapy while the reported 
rate of non responders is 3 – 20% in various studies. Though these 9 patients did 
not respond to chemotherapy in terms of tumour size reduction or vascularity, 
all of them achieved resolution of skin and chest wall invasion, making them 
operable. This adds to the evidence regarding the usefulness of neoadjuvant 
chemotherapy in inoperable breast malignancy. 
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Tumour size had a significant relationship with response to chemotherapy 
with tumours smaller than 5 cm and larger than 10 cm showing a less 
favourable response when compared to tumours between 5 and 10 cm in size. 
Also the tumours which had a volume between 75 and 150 cc had a better 
response rate than those with volumes below 75cc or above 150cc. This is in 
contrast to Gajdos et al who reported better response rates in smaller 
tumours.
[85]
 
Clinical assessment overestimated complete response in 26% . . Sun et al 
reported a false complete remission rate of  46.8% while in our study it was 
66.7%. While considering the ability of clinical examination to predict overall 
response, it had a low positive predictive value (33.5%) and specificity (69.5%) 
though the negative predictive value (97%)  and sensitivity (87.5%) were very 
high.  Also it underestimated response in 44% of cases.
[22]
 This trend is seen in 
other studies also. Feldman et al and Cocconi et al have also reported higher 
false positive rates in assessment of response by clinical methods.
[14,21]
 Khoker 
et al found that the initial clinical response after the first cycle of chemotherapy 
predicted final clinical response well. But out of the 15 patients who showed 
initial clinical response, only 6 (40%) patients achieved pathological complete 
response.
[18]
 von Minckwitz et al have reported that early clinical response (after 
the second cycle) is  good predictor for pathological complete response  but it 
was not an independent predictor.
[20]
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The problem with clinical examination is that small areas of residual 
viable tumour cells may not be palpable. The presence of fibrotic reaction 
makes it even more difficult to identify small residual masses by palpation. 
Also, it is impossible to differentiate a fibrotic mass and post intervention 
inflammation from tumour mass. 
B mode ultrasonography  is not a reliable method of assessment of both 
pathological complete response and lack of response. It correctly identified only 
3 out of the eight complete responders (37.5%). As B mode ultrasound 
measures only the size of the tumour, in cases where the tumour size remains 
the same in spite of it being replaced by non viable fibrotic or necrotic tissue 
due to the effect of chemotherapy, ultrasound is not able to identify the 
response. Its ability to identify non responders is limited by the changes in 
echogenicity of the tumour after chemotherapy, which may make it difficult for 
the examiner to differentiate the tumour from the surrounding tissue. The 
tumour may become isoechoic to the surrounding tissue or may develop 
afibrotic reaction in the surrounding tissue making the distinction of tumour 
margins unidentifiable in either case. 
Imaging the vascularity of tumours helps us avoid the pitfalls of 
morphological imaging. As tumour angiogenesis is a very important 
phenomenon in tumour survival and growth, changes in vascularity closely 
reflect the change in the viability of tumour cells. Thus were are able to identify 
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correctly, the absence of tumour tissue in a clinically palpable, sonographically 
visible mass and the presence of viable tumour in an area which is impalpable 
and sonographically unidentifiable. 
Doppler, which is the least expensive method of imaging vascularity, is 
the only practical option in less well developed countries which are short of the 
monetary resources required to battle the rising incidence of cancer. The ability 
to predict the lack of response early not only helps us save the patient from the 
toxic effects of the ineffective drugs and offer her alternatives for better disease 
control but also prevent wastage of expensive chemotherapeutic drugs to which 
some other patient would be sensitive and therefore be benefitted. 
It has been proven that the interstitial pressure of the tumour 
microenvironment is increased due to accumulation of osmotically active 
macromolecules in the interstitium  caused by the increased vascular 
permeability of tumour vessels.
[86]
 As the tissue oncotic pressure (interstitial 
pressure) reaches the level of hydrostatic pressure of blood vessels, the tissue 
perfusion pressure becomes almost nulled as according to Starlings hypothesis, 
Tissue perfusion pressure  = hydrostatic pressure – tissue oncotic 
pressure. 
Further increases in interstitial pressure cause the tumour blood vessels to 
collapse by mechanical compression. 
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It could be construed that this increase in interstitial pressure causing 
resistance to flow is reflected by resistivity index in Doppler. But this effect 
could be counter balanced by the arteriovenous shunts which known to be are 
abundant in the tumour vessels. When AV shunts are present the blood is not 
exposed to the the resistance of the increased IFP and instead channelized into 
the low resistance pathway, the veins. 
But the tumour microenvironment is very heterogeneous. So a tiny area 
of increased interstitial pressure could be adjacent to an area of normal 
interstitial pressure. This could be the reason why there are conflicting reports 
about the RI values in malignancies.
[77,79,87]
 
In our study, the baseline RI was significantly different between the 
responders and non responders with the non responders having a higher RI. This 
may be explained by the fact that drug delivery to tumours having an increased 
interstitial fluid pressure is less than optimal. Vavra et al have proved that 
intravenously injected 
14
C-labelled sucrose was concentrated in the necrotic 
areas and surrounding normal tissue (where the interstitial pressure is lower) 
rather than the areas of viable tumour.
[87]
 
In our study, we took multiple measurements and used the lowest RI for 
analytical purpose following Osanai et al. The lowest RI could represent an area 
where the interstitial pressure was not high enough to cause substantial increase 
in vascular resistance. The baseline RI had a significant correlation with the 
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histological grade of the tumour with higher grade tumors having a lower RI. 
This is in concordance with a study by Osanai et al where they found that grade 
3 tumours had a lesser RI than grade 1 tumours.
[73]
 
The complete disappearance of vascular signals was an independent 
predictor of pathological complete response with a specificity of 98% and 
positive predictive value of 83.3%. Kumar et al have recently reported the value 
of this finding. While counting the number of colour signals within an area of 1 
cm
2 
is cumbersome when there is no dedicated software, gross reductions in 
flow can be made out reliably on visual inspection by an experienced 
sonologist.
[71]
 Huber et al have stated that a change in vascularity of the 
magnitude of 5% can be detected visually.
[29]
  
In our study there was a uniform increase in RI in patients who responded 
to chemotherapy. In many other studies there was no dominant increase or 
decrease in RI with therapy that was significantly different between responders 
and non responders.
[71,72]
 Oksuzoglu et al have reported that there was a uniform 
decrease in RI in responders in the 21 patients of LABC studied.
[77]
 But many 
studies conducted in patients with locally advanced carcinoma of the cervix 
have reported that there was an an increase in RI with response to 
chemoradiotherapy.
[80,81]
 
It could be postulated that in tumors that respond to chemotherapy, the 
interstitial fluid may not be very high (as very high interstitial fluid pressure is 
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an important impediment to optimal drug delivery).
[88]
 (In our study too, we 
found that non responders had a higher baseline RI). In these cases the AV 
shunting in the tumour vasculature may play a substantial role in the flow 
resistance. With normalization of the vasculature with response to 
chemotherapy, the AV shunting is reduced and there is an increase in RI. This 
hypothesis needs to be verified by experiments on tumour microenvironment. 
The vascular response based on the cumulative doppler score at the end 
of chemotherapy had a good sensitivity, specificity and negative predictive 
value for prediction of both complete responders (80%, 93.5% and 96%) and 
non responders (78%, 98% and 96%). It scored far better than clinical 
examination and B mode ultrasonography. Similar results have been obtained 
by many of the recently published studies. Kumar et al reported a sensitivity of 
66% for doppler on comparison with 45% for clinical examination.
[71]
 Kedar et 
al and singh et al have also reported good sensitivity of doppler to predict 
pathological response.
[65,72]
 
The agreement rate between pathological response and doppler 
assessment has been found to be very good with a kappa value of 0.77. This 
surpassed the agreement between HPE and clinical examination and B mode 
ultrasonography. This is in concordance with Huber et al who found substantial 
agreement between doppler and HPE with a kappa value of 0.87.
[29]
 Balu 
81 
 
maestro et al have also reported a high correlation between doppler and 
pathological response.
[30]
 
The accuracy of doppler assessment which reflects the proportion of 
correct predictions is the highest for doppler at 85%, when compares to 61% for 
clinical examination and 70% for B mode ultrasonography. 
The time and effort involved in any method employed to predict 
chemotherapeutic response is justified only when it is cost effective and 
clinically applicable and beneficial in the management of patients.. 
The main aim of this study was to be able to predict the response or the 
lack thereof to chemotherapy by an interim assessment before the completion of 
the regimen. Only then would we be able to make meaningful changes in the 
treatment of individual patients thus maximizing the benefit and minimizing the 
cost of therapy. In our study we assessed the response after each cycle in order 
to determine whether such early prediction using an inexpensive method like 
Doppler was possible and if possible to determine how early the response could 
be reliably predicted. We found that Doppler was very advantageous in this 
respect. We assessed clinical examination and B mode ultrasound alongside the 
Doppler parameters of RI and number of flow signals per unit area at the end of 
second cycle of chemotherapy. The cut off taken was the failure to achieve a 
25% change from the baseline value. In case of RI, the expected change was an 
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increase with tumour response while all other parameters were expected to 
decrease following tumour response to chemotherapy. 
We found that the Doppler parameters scored better than clinical 
examination and B mode ultrasound in sensitivity, specificity, positive 
predictive value and negative predictive value. RI had a better sensitivity and 
negative predictive value (90% and 97% respectively) while the number of flow 
signals per unit area had a better specificity and positive predictive value (93% 
and 67%).  
RI can be measured easily in the tumour vessels if they can be visualised. 
The tortuosity of the tumour vessels donot hamper the measurement of RI as it 
would the velocity measurements, which are angle dependent.  
Peak systolic velocity measurements were not useful in predicting the 
response in our study while Singh et al have reported decrease in PSV with 
response to chemotherapy. The main pitfall encountered by us in PSV 
measurement was due to the extreme tortuosity of the tumour vessels making 
angle correction almost impossible. 
There were a few limitations to this study.  
We did not use any specialized software for the quantification of number 
of flow signals per unit area of the tumour. Also power doppler was not used. 
These facilities involved additional expenditure and our study was aimed 
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primarily at cost reduction. In spite of these disadvantages this study shows that 
a basic colour doppler gives valuable information and reliably predicts the 
response early during the course of chemotherapy. 
In this study comparison of doppler with dynamic contrast enhanced MRI 
which is now considered as the imaging gold standard, could not be done as it 
involved huge expense. 
The accuracy of the velocity measurements could not be assured as the 
tumour vessels seldom followed a course straight enough to correct the doppler 
angle. In measuring the RI, the lowest value out of the multiple measurements 
taken was used for analysis, the rationale behind it being the vessel with the 
lowest RI was the main supplier as it showed the lowest resistance to blood 
flow. Osanai et al have used a similar concept in their study.
[73]
 
In our study we considered the response of only the primary tumour and 
did not consider doppler imaging of the axilla. The nodal response is also 
considered a very important prognosticator and so further studies should be 
done to evaluate the doppler assessment of nodal response too.  
Ultrasonography and doppler are very operator dependent. In order to 
reduce the inter observer variability, all the doppler examinations in this study 
was done by a single examiner. The clinical assessment was also done by a 
single person for all cases. 
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Doppler ultrasonography has been found to be a non invasive, relatively 
inexpensive and reproducible method of assessment of response to primary 
systemic chemotherapy in patients with locally advanced breast cancer. Since it 
directly visualizes the vessels and assesses tumour vasculature both 
qualitatively and quantitatively, it is a good method to image neoangiogenessis 
and vasculogenesis. It not only correlates very well with histopathological 
response, but also predicts the pathological response with good accuracy as 
early as after 2 cycles of chemotherapy. Though in this study assessment was 
done after every cycle, based on the results obtained, we suggest that a pre 
treatment baseline assessment and an interim assessment at the end of second 
cycle would suffice for accurate response prediction.  
SUMMARY 
The study titled “Doppler ultrasound assessment of tumour vascularity in 
locally advanced breast cancer at diagnosis and following primary systemic 
chemotherapy” was a prospective study of 54 patients with newly diagnosed 
LABC admitted in Rajiv Gandhi Government General Hospital, Chennai. 
Eligible patients underwent clinical examination, ultrasonography and colour 
doppler imaging with measurement of doppler indices at baseline and prior to 
every cycle of chemotherapy. All patients underwent definitive mastectomy 
after four cycles of chemotherapy with documentation of tumour size on 
pathological specimen. The correlation between various modalities of response 
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assessment and histopathological results was analysed. There were no 
significant pre-treatment clinical characteristics that predicted response. High 
vascularity at baseline correlated with good response. The cumulative Doppler 
score employed in this study was useful in identifying responders and non 
responders as early as post second cycle of chemotherapy with a high sensitivity 
and specificity. Doppler imaging had a better correlation with histology 
compared to other modalities.  
This study highlights the fact that combining Doppler imaging with the 
routine clinical examination for response assessment could increase the 
sensitivity and specificity of both the methods and can identify non responders 
earlier.  
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CONCLUSIONS 
1. Colour Doppler imaging was a better modality for response assessment 
than clinical examination or ultrasonography. 
2. Assessment by Doppler imaging had highest correlation with 
histopathology. 
3. A cumulative score based on Doppler indices had a high specificity and 
sensitivity for identifying non responders and responders. 
4. Hypervascular tumours had better response to chemotherapy than 
hypovascular tumours. 
5. Failure of vascularity to decrease at least by 25% after the second cycle 
of chemotherapy had a high sensitivity, specificity and positive predictive 
value for non responsiveness to chemotherapy. 
6. Failure of resistive index to increase during chemotherapy had a high 
sensitivity, specificity and positive predictive value for identifying non 
responders.  
7. A baseline, interim and post chemotherapy Doppler imaging is useful in 
identifying non responders accurately. 
8. Combining Doppler imaging with clinical examination could accurately 
predict response in most cases, hence can be recommended in the routine 
assessment of response. 
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Morphological responder  showing decrease in tumour size 
on chemotherapy 
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Morphological non-responder showing  increase in 
tumour size following chemotherapy. 
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Vascular responder showing  serial increase in 
RI following chemotherapy 
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Vascular non-responder showing no significant 
change in RI 
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Vascular responder showing decrease in flow 
signals following chemotherapy 
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Vascular non-responder showing no significant 
decrease in flow signals 
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                                    INFORMED CONSENT FORM 
Title of the study: “Doppler Ultrasound Assessment Of Tumour Vascularity In 
Locally Advanced Breast Cancer At Diagnosis And Following Primary 
Systemic Chemotherapy”. 
      Name of the principal investigator DR. R.S.Aarathhi Dhevi 
                  Post graduate, M.D(Radiodiagnosis) 
                  Madras Medical College.Chennai-3 
Name of the institution: Rajiv Gandhi Government Hospital, Chennai-3 
1. I understand that if I am found eligible, I may undergo certain extra tests 
and special studies which in any way do not affect my final report or 
management. 
2. I have read and understood this consent form and the information 
provided to me. 
3. I have been explained the nature of the study 
4. I have had the consent from explained to me. 
5. My rights and responsibilities are explained to me by the investigator. 
6.  I agree to cooperate with the investigator and inform her if I have 
unusual symptoms 
7. I am aware of the fact that I can opt out of the study at any time without 
any reason and I am assured that this will not affect my treatment in this 
hospital 
8. I hereby give permission to the investigator to release the information of 
the study and I will not have any control over the results of this study 
9. I am giving my consent in full consciousness for this study to undergo 
clinical examination, breast ultrasonogram and color doppler study. 
   10.  I give my consent to undergo chemotherapy and surgery when required, 
the nature of illness and consequences of treatment have been clearly explained 
to me. 
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   11.  I give permission to use my results wherever required. 
   12. My identity will be kept confidential if my data are publicly presented 
I was free to ask questions and they have been answered. I am over 18 yrs of 
age and exercising my free power of choice, here by I am giving consent to be 
included as participant in the study titled “Doppler Ultrasound Assessment Of 
Tumour Vascularity In Locally Advanced Breast Cancer At Diagnosis And 
Following Primary Systemic Chemotherapy”. 
 
 
Patient‟s signature/thumb impression:                                                  date:  
 
 Name and address: 
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ஆராய்ச்சி ஒப்புதல் கடிதம் 
ஆராய்ச்சி தலைப்பு: 
நிகவும் தீவிபநா஦ நார்஧கப் புற்றுந஥ாய் உள்஭ ந஥ானா஭ிக஭ில் புற்றுந஥ாய் 
நருந்து சிகிச்சசக்கு முன்னும் ஧ின்னும் “க஬ர் டாப்஬ர்” மூ஬ம் சிகிச்சசனின் 
஧னன்஧ாடு ஧ற்஫ி அ஫ிதல். 
ப஧னர்: நததி: 
வனது: உள்ந஥ானா஭ி எண்: 
஧ால்: ஆபாய்ச்சி நசர்க்சக எண்: 
1. ஥ான் இந்த ஆய்வுக்கு தகுதினா஦வபாகக் கருதப்஧ட்டால், சி஬ சி஫ப்பு 
஧ரிநசாதச஦களுக்கு உட்஧ட ந஥ரிடும் என்றும், அத்தசகன 
஧ரிநசாதச஦கள் எ஦து இறுதி அ஫ிக்சகசனநனா அல்஬து சிகிச்சச 
முச஫சனநனா ஧ாதிக்க நாட்டா என்றும் அ஫ிந்து பகாண்நடன். 
2. இந்த ஆபாய்ச்சினின் விவபங்களும், அதன் ந஥ாக்கங்களும் எ஦க்குத் 
பத஭ிவாக வி஭க்கப்஧ட்ட஦.  
3. எ஦க்கு வி஭க்கப்஧ட்ட விஷனங்கச஭ப் புரிந்து பகாண்டு ஥ான் எ஦து 
சம்நதத்சதத் பதரிவிக்கிந஫ன். 
4. இந்த ஆபாய்ச்சினில் ஧ி஫ரின் ஥ிர்஧ந்தநின்஫ி என் பசாந்த விருப்஧த்தின் 
ந஧ரில் தான் ஧ங்குப஧பறுகிந஫ன் நற்றும் ஥ான் இந்த ஆபாய்ச்சினில் 
இருந்து எந்ந஥பமும் ஧ின்வாங்க஬ாம் என்஧சதம௃ம் அத஦ால் எந்த 
஧ாதிப்பும் ஏற்஧டாது என்஧சதம௃ம் புரிந்து பகாண்நடன்.  
5. ந஥ானின் தன்சந ஧ற்஫ிம௃ம், சிகிச்சச முச஫னின் ஧க்கவிச஭வுகள் 
஧ற்஫ிம௃ம் எ஦க்குத் பத஭ிவாக எடுத்துசபக்கப்஧ட்டது. 
6. ஥ான் என்னுசடன சுன஥ிச஦வுடனும் முழு சுதந்திபத்துடனும் இந்த 
நருத்துவ ஆபாய்ச்சினில் என்ச஦ நசர்த்துக்பகாள்஭ சம்நதிக்கிந஫ன். 
7. எ஦க்கு புற்றுந஥ாய் நருந்து பசலுத்துவதற்கும், நதசவப்஧டும் ந஥பத்தில் 
அறுசவ சிகிச்சச பசய்து பகாள்வதற்கும் முழுந஦துடன் 
சம்நதிக்கிந஫ன். 
8. எ஦து ந஥ாய் ஧ற்஫ின ஆவணங்கச஭ப் ஧னன்஧டுத்திக்பகாள்஭ 
முழுந஦துடன் சம்நதிக்கிந஫ன்.  
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9. இந்த ஆபாய்ச்சிக் கட்டுசப பவ஭ினிடப்ப்஧டும்ப஧ாழுது என்ச஦ப் ஧ற்஫ின 
த஦ிப்஧ட்ட தகவல்கள் பவ஭ினிடப்஧ட நாட்டாது என்றும் அ஫ிந்து 
பகாண்நடன். 
 
சகபனாப்஧ம்                     
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PROFORMA 
Name:     S. No: 
Age:      IP no:  
Address 
 
Complaints 
 
Duration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical examination: 
 Right left 
Nipple 
 
  
Skin involvement 
 
  
Lump size 
 
  
Quadrant 
 
  
Ulcer 
 
  
Chest wall involvement 
 
  
Dilated veins 
 
  
Mobility  
 
  
Skin over the surface   
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Axilla:  
 Right left 
Number of nodes 
 
  
Mobility 
 
  
Consistency 
 
  
Lymphedema  
 
  
 
Supraclavicular area: 
 Right Left 
Number of nodes 
 
  
Consistency 
 
  
Mobility 
 
  
 
Others: 
Cervical nodes: 
Respiratory system: 
Cardiovascular system: 
Hepatomegaly: 
Ascites: 
Gynec examination: 
Nervous system: 
Spine: 
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INVESTIGATIONS 
HPE: 
 
PREOP STAGE: 
PRECHEMO: 
 HEMOGRAM 
 RENAL FUNCTION 
 LIVER FUNCTION 
 ECG 
 ECHOCARDIOGRAM 
 
CLINICAL EXAMINATION: (RESPONSE) 
 BASELINE CHEMO I CHEMO II 
CHEMO 
III 
CHEMO 
IV 
TUMOR 
SIZE 
     
MOBILITY      
SKIN      
CHEST 
WALL 
     
AXILLA      
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SONOMAMMOGRAM (RESPONSE): 
 BASELINE CHEMO I CHEMO II 
CHEMO 
III 
CHEMO 
IV 
TUMOR 
SIZE 
     
SKIN      
CHEST 
WALL 
     
AXILLA      
 
 
DOPPLER OF TUMOR (RESPONSE): 
 BASELINE CHEMO I CHEMO II 
CHEMO 
III 
CHEMO 
IV 
PSV      
EDV      
RI      
PI      
FEEDER 
VESSELS 
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POST OPERATIVE DETAILS 
PROCEDURE: 
POST OP HPE: 
 TUMOR SIZE: 
 MICROSCOPY: 
 
 NOTTINGHAM INDEX: 
 GRADE: 
 LYMPHATIC INVASION: 
 VASCULAR INVASION: 
 MARGINS: 
 LYMPH NODES: 
 
 RESPONSE:  COMPLETE 
                        PARTIAL  
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KEY TO MASTER CHART 
 
CR  : Complete Response 
ER : Estrogen Receptor 
F : Fixed 
HPE : Histopathological Examination 
I : Involved 
IDC : Infiltrating Ductal Carcinoma 
L : Left sided 
LI : Lymphatic invasion 
M : Mobile 
N : Negative 
NEC : Neuroendocrine Carcinoma 
NI : Not Involved  
NOS : Not Otherwise Specified 
NR : No Response 
P : Positive 
PgR : Progesterone Receptor 
PR : Partial Response 
PSV : Peak Systolic Velocity 
R :  Right Sided 
RI :  Resistivity Index 
VI : Vascular Invasion 
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TURNITIN ANTI PLAGIARISM RESULT 
 
 
 
 
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4
1 157/12 45 IDC NOS 1 T4BN2M0 IIIB R 18*17 10*11 9*7 7*6 6*7 I I I I NI NI NI NI NI NI 2 2 1 1 1 3*2 3*2 2*2 1*1 1*1 F F M M M PR
2 259/12 57 IDC NOS 2 T4BN2M0 IIIB R 12*10 10*12 11*10 10*8 9*8 I I I NI NI NI NI NI NI NI 3 3 2 1 1 2*1 2*1 1*1 1*1 NS M M M M M NR
3 274/12 37 IDC NOS 2 T4BN3M0 IIIC L 12*11 10*9 10*10 10*10 9*10 I I I NI NI NI NI NI NI NI 3 1 1 1 1 3*2 3*2 2*2 1*1 1*1 M M M M M NR
4 209/12 65 IDC NOS 2 T4BN1M0 IIIB R 9*8 6*7 5*5 4*4 4*4 I I I NI NI NI NI NI NI NI 3 2 1 1 1 2*1 2*2 1*1 1*1 <1 M M M M M PR
5 172/12 50 IDC NOS 2 T4BN1M0 IIIB R 5*4 5*4 5*5 4*3 4*3 I I I NI NI NI NI NI NI NI 2 2 1 1 1 2*2 2*2 <1 <1 <1 M M M M M NR
6 339/12 45 IDC NOS 2 T4BN1M0 IIIB L 5*4 5*5 4*4 4*3 3*3 I I I NI NI NI NI NI NI NI 1 1 1 1 1 2*2 1*2 2*1 1*1 1*1 F M M M M NR
7 429/12 66 IDC NOS 2 T4BN1M0 IIIB L 9*8 7*6 5*4 5*4 4*4 I NI NI NI NI NI NI NI NI NI 1 1 1 1 1 2*1 1*1 1*1 <1 <1 M M M M M PR
8 255/12 47 IDC NOS 3 T3N3M0 IIIC L 8*8 3*4 2*2 0 0 NI NI NI NI NI NI NI NI NI NI 1 1 1 1 0 1*1 1*1 <1 <1 <1 M M M M M CR
9 426/12 54 IDC NOS 2 T4BN1M0 IIIB L 8*6 4*4 0 0 0 NI NI NI NI NI NI NI NI NI NI 2 1 1 1 0 3*2 2*2 2*1 1*1 0 M M M M 0 CR
10 418/12 45 IDC NOS 2 T4BN1M0 IIIB R 7*6 3*2 1*1 0 0 I I NI NI NI NI NI NI NI NI 1 1 1 0 0 3*2 <1 <1 0 0 M M M 0 0 CR
11 352/12 60 IDC NOS 2 T4BN2M0 IIIB L 7*5 5*5 5*5 4*4 3*3 I I NI NI NI NI NI NI NI NI 2 2 2 1 1 3*3 3*3 2*2 1*1 <1 F F F M M PR
12 378/12 37 IDC NOS 1 T4BN1M0 IIIB L 12*10 8*9 8*9 9*10 6*7 I I I NI NI NI NI NI NI NI 1 1 1 1 1 2*1 1*1 1*1 1*1 <1 M M M M M PR
13 540/12 60 IDC NOS 1 T4BN3M0 IIIC R 6*5 5*5 4*3 3*2 0 I I I NI NI NI NI NI NI NI 2 2 1 1 0 1*1 1*1 1*1 <1 <1 M M M M M CR
14 498/12 38 IDC NOS 2 T3N2M0 IIIA L 6*6 5*4 0 0 0 NI NI NI NI NI NI NI NI NI NI 2 2 2 1 1 2*2 2*2 2*1 2*1 0 F F M M M CR
15 781/12 45 IDC NOS 2 T4CN2M0 IIIB L 12*8 6*4 4*5 0 0 I I I NI NI I I I NI NI 2 2 1 1 1 2*2 2*2 2*1 1*2 1*1 F F M M M CR
16 787/12 57 IDC NOS 3 T4BN1M0 IIIB L 8*7 6*6 4*6 4*3 2*1 I I NI NI NI NI NI NI NI NI 3 2 1 1 1 3*2 2*2 1*2 1*1 1*1 M M M M M PR
17 619/12 50 IDC NOS 3 T4BN2M0 IIIB R 10*8 6*6 5*4 4*4 0 I I I NI NI NI NI NI NI NI 2 1 1 1 1 2*2 2*1 1*1 1*1 <1 M M M M M CR
18 698/12 45 IDC NOS 3 T4BN1M0 IIIB L 20*15 12*6 6*7 4*5 2*3 I I NI NI NI NI NI NI NI NI 3 2 1 1 1 3*2 2*2 1*1 1*1 <1 M M M M M PR
19 569/12 50 IDC NOS 1 T4BN1M0 IIIB L 7*6 5*6 5*6 4*3 2*2 I NI NI NI NI NI NI NI NI NI 3 2 1 1 1 3*2 2*2 2*2 <1 <1 M M M M M PR
20 710/12 65 IDC NOS 3 T4BN1M0 IIIB L 12*9 5*6 3*3 2*1 1*1 I I NI NI NI NI NI NI NI NI 3 3 2 1 0 3*3 3*2 2*1 1*1 0 M M M M M PR
21 565/12 65 IDC NOS 2 T4BN3M0 IIIC L 5*5 5*5 5*5 4*3 3*2 I I NI NI NI NI NI NI NI NI 2 2 1 1 1 3*2 2*2 2*1 1*1 1*1 M M M M M NR
22 695/12 58 IDC NOS 1 T4BN1M0 IIIB L 8*6 5*5 2*2 2*1 1*1 I I NI NI NI NI NI NI NI NI 3 2 1 1 1 2*2 1*1 <1 <1 <1 M M M M M PR
23 493/12 40 IDC NOS 1 T4BN1M0 IIIB L 8*6 5*4 0 0 0 I I NI NI NI NI NI NI NI NI 1 1 1 0 0 2*1 2*1 1*1 0 0 M M M M M CR
24 529/12 55 IDC NOS 2 T4BN1M0 IIIB L 10*8 5*5 4*3 1*2 0 I I NI NI NI NI NI NI NI NI 2 1 1 1 0 2*2 2*1 1*1 <1 <1 M M M M M CR
25 507/12 67 IDC NOS 2 T4BN3M0 IIIC L 7*7 4*3 0 0 0 I I NI NI NI NI NI NI NI NI 2 1 1 0 0 2*2 1*1 1*1 0 0 M M M M M CR
26 609/12 55 IDC NOS 3 T4BN2M0 IIIB R 12*10 6*6 0 0 0 I I NI NI NI NI NI NI NI NI 3 2 1 0 0 1*1 2*1 <1 <1 0 F M M M M CR
27 70/12 45 IDC NOS 1 T4BN1M0 IIIB R 6*5 4*4 5*3 4*4 3*4 I I NI NI NI NI NI NI NI NI 2 1 1 1 1 2*2 1*1 <1 <1 <1 M M M M M PR
28 659/12 27 IDC NOS 2 T4BN1M0 IIIB R 10*8 6*4 2*3 0 0 I I NI NI NI NI NI NI NI NI 2 1 1 0 0 2*1 1*1 1*1 <1 <1 M M M M M CR
29 760/12 55 IDC NOS 2 T4BN1M0 IIIB L 10*10 8*9 9*9 7*5 5*5 I I NI NI NI NI NI NI NI NI 3 1 1 1 1 2*2 1*1 <1 <1 <1 M M M M M PR
30 761/12 56 IDC NOS 2 T4BN0M0 IIIB R 7*5 5*5 4*3 3*3 3*3 I I NI NI NI NI NI NI NI NI 0 0 0 0 0 0 0 0 0 0 - - - - - PR
31 657/12 55 IDC NOS 1 T3N2M0 IIIA L 8*6 5*4 3*3 4*4 4*3 NI NI NI NI NI NI NI NI NI NI 3 2 1 1 1 1*1 2*2 1*1 <1 <1 F F M M M PR
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32 847/12 55 IDC NOS 3 T4BN2M0 IIIB R 12*10 6*7 0 0 0 I I NI NI NI NI NI NI NI NI 3 2 2 2 2 3*2 3*3 2*1 1*1 1*1 F F M M M CR
33 854/12 46 IDC NOS 1 T4BN2M0 IIIB L 10*10 8*7 7*7 6*6 4*4 I I NI NI NI NI NI NI NI NI 1 1 1 1 0 2*1 2*1 1*1 <1 0 F M M M M PR
34 897/12 48 IDC NOS 2 T4BN1M0 IIIB L 9*8 0 0 0 0 I I NI NI NI NI NI NI NI NI 1 1 1 1 1 3*2 1*1 <1 <1 0 M M M M M CR
35 860/12 50 IDC NOS 3 T4BN1M0 IIIB R 5*5 4*5 5*7 8*10 12*8 I I I I I NI NI NI NI NI 3 2 2 2 1 2*2 2*2 3*2 3*2 2*2 M M M M M NR
36 898/12 50 IDC NOS 2 T4BN1M0 IIIB L 8*8 6*6 0 0 0 I NI NI NI NI NI NI NI NI NI 4 3 1 1 0 2*1 11 <1 <1 <1 M M M M M CR
37 899/12 58 IDC NOS 3 T4BN1M0 IIIB L 5*5 3*3 1*2 0 0 I NI NI NI NI NI NI NI NI NI 3 2 1 1 0 1*1 1*1 1*1 <1 0 M M M 0 0 CR
38 918/12 65 IDC NOS 2 T3N3M0 IIIC R 10*8 8*8 6*5 4*3 2*2 NI NI NI NI NI NI NI NI NI NI 4 3 1 1 1 2*2 2*1 1*1 1*1 <1 M M M M M PR
39 882/12 56 IDC NOS 2 T4BN3M0 IIIC R 4*4 4*4 3*2 2*2 2*2 I NI NI NI NI NI NI NI NI NI 3 2 1 1 1 2*1 1*1 1*1 <1 <1 M M M M M NR
40 994/12 54 IDC NOS 3 T3N3M0 IIIC R 8*8 0 0 0 0 NI NI NI NI NI NI NI NI NI NI 1 1 0 0 0 3*2 2*3 <1 0 0 M M - - - CR
41 904/12 46 IDC NOS 2 T4BN1M0 IIIB R 6*6 0 0 0 0 I NI NI NI NI NI NI NI NI NI 1 0 0 0 0 2*2 1*1 <1 0 0 M M M - - CR
42 1101/12 45 IDC NOS 1 T4BN2M0 IIIB R 6*4 5*5 5*5 4*5 5*5 I NI NI NI NI NI NI NI NI NI 4 4 2 1 1 3*2 2*2 2*2 2*2 2*2 F F M M M NR
43 1090/12 44 IDC NOS 2 T4BN1M0 IIIB L 9*8 7*4 5*5 5*4 3*2 I NI NI NI NI NI NI NI NI NI 3 2 2 2 1 2*2 1*2 1*1 <1 <1 M M M M M PR
44 926/12 47 IDC NOS 1 T4BN1M0 IIIB L 10*8 8*8 7*8 5*5 4*3 I NI NI NI NI NI NI NI NI NI 3 2 2 2 1 2*3 2*1 1*1 <1 <1 M M M M M PR
45 947/11 45 IDC NOS 3 T4BN3M0 IIIC L 9*9 5*4 3*3 3*2 2*2 I I NI NI NI NI NI NI NI NI 3 2 1 1 1 2*2 1*2 1*1 <1 <1 M M M M M PR
46 1159/12 56 IDC NOS 3 T4BN2M0 IIIB L 12*8 10*8 8*6 6*6 5*5 I I I NI NI NI NI NI NI NI 3 3 2 1 1 2*3 2*2 1*2 1*1 <1 M M M M M PR
47 1157/12 49 IDC NOS 1 T4BN1M0 IIIB R 5*4 4*4 0 0 0 I I NI NI NI NI NI NI NI NI 2 2 1 1 1 2*3 2*2 1*1 1*1 <1 M M M M M CR
48 1199/12 46 IDC NOS 1 T4CN1M0 IIIB R 12*10 8*8 5*5 5*4 3*4 I I NI NI NI I I NI NI NI 3 2 2 2 2 2*2 2*2 1*1 <1 <1 M M M M M PR
49 1312/12 45 IDC NOS 2 T3N3M0 IIIC R 7*7 5*6 6*6 4*4 3*5 NI NI NI NI NI NI NI NI NI NI 2 2 1 1 1 1*1 1*1 <1 <1 <1 M M M M M PR
50 1381/12 48 IDC NEC 1 T4BN1M0 IIIB L 8*6 4*3 2*3 2*2 2*2 I I NI NI NI NI NI NI NI NI 2 1 1 1 1 2*1 1*1 1*1 <1 <1 M M M M M PR
51 1280/12 40 IDC NOS 1 T4BN2M0 IIIB L 10*8 9*9 9*8 7*7 7*6 I I I NI NI NI NI NI NI NI 3 1 1 1 1 2*2 2*1 1*1 <1 <1 F F M M M NR
52 1422/12 45 IDC NOS 2 T4BN1M0 IIIB L 15*10 6*7 5*4 3*4 0 I I NI NI NI NI NI NI NI NI 3 2 1 1 1 2*2 1*1 <1 <1 0 M M M M M CR
53 315/12 60 IDC NOS 2 T3N3M0 IIIC L 12*10 4*3 0 0 0 I NI NI NI NI NI NI NI NI NI 2 1 1 1 0 1*1 1*1 1*1 <1 0 M M M M - CR
54 1112/12 55 IDC NOS 1 T4BN2M0 IIIB R 6*5 4*4 2*3 3*3 2*2 I NI NI NI NI NI NI NI NI NI 1 1 1 1 1 1*1 1*1 <1 <1 <1 M M M M M PR
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236 220 234 226 230 3*3 2*3 2*1 2*2 2*2 NR 10.2 9.8 10.3 9.6 8.9 0.72 0.65 0.5 0.5 0.46 9 7 8 6 7 NR 15*10 Y Y I 006/006 NR N N P T4BN2M0
98 100 78 80 80 3*1 2*1 1*1 1*1 <1 NR 23.3 36.3 21.2 7.8 19.9 0.63 0.54 0.55 0.53 0.5 8 9 6 6 6 NR 8*6 Y Y NI 003/7 NR P P P T3N1M0
180 175 198 180 190 1*1 2*3 3*3 2*2 1*2 NR 40 49 30 110 78 0.67 0.54 0.55 0.49 0.44 9 9 7 6 7 NR 8*6 Y Y I 002/5 NR N N N T4BN1M0
110 90 86 64 52 2*1 <1 0 0 0 PR 28.9 15.9 19.2 94.2 22.3 0.58 0.67 0.74 0.78 0.79 6 5 2 3 2 PR 4*4 N N NI 002/2 PR P P N T2N1M0
55 60 58 55 55 2*2 2*2 <1 <1 <1 NR 56.8 19.2 15.8 26.3 22.9 0.6 0.58 0.62 0.42 0.4 6 5 6 7 7 NR 5*4 Y Y NI 002/7 NR P P P T2N1M0
60 56 54 50 50 2*2 2*2 2*1 2*1 1*1 NR 54.3 64.7 54.2 49.8 9.85 0.71 0.66 0.62 0.56 0.5 9 8 8 6 6 NR 4*4 Y Y NI 003/10 NR N P P T2N1M0
54 56 40 34 32 2*1 1*1 <1 <1 <1 NR 42.8 44.8 23.2 28.4 30.1 0.7 0.76 0.8 0.8 0.8 9 6 3 3 1 PR 2*1 Y Y NI 001/7 PR P P N T1N1M0
96 56 34 24 20 1*1 1*1 1*1 <1 <1 PR 23.1 19.3 16.7 12.9 16.8 0.56 0.76 0.78 0.82 0.88 11 6 2 1 1 PR 2*2 Y Y NI 005/8 PR P P N T1N2M0
120 70 40 15 15 1*1 1*1 1*1 0 0 PR 20.9 27.1 15.8 29.1 38.6 0.68 0.84 0.86 0.86 0.9 4 4 4 5 1 PR 5*4 Y Y NI 001/3 NR N N N T1N1M0
98 36 24 0 0 3*2 2*2 1*1 0 0 CR 47.2 39.8 15.8 20.6 0 0.68 0.86 0.86 0.92 0 5 4 4 2 1 CR 0 - - - 0/7 CR N N P T0N0M0
100 90 90 65 50 2*2 3*1 2*1 1*1 <1 PR 32.5 35.7 13.2 12 8.8 0.54 0.68 0.7 0.74 0.88 8 3 2 2 1 PR 2*1 Y Y NI 001/6 PR P P N T1N1M0
178 134 126 148 98 3*2 3*2 3*1 2*2 2*2 NR 15 15.3 30.3 42.8 15.9 0.84 0.79 0.55 0.62 0.78 3 1 2 4 1 PR 4*3 Y Y NI 005/9 PR P P N T2N2M0
110 90 45 30 25 1*1 1*1 <1 <1 <1 PR 34.7 15.8 19.2 0 0 0.72 0.76 0.76 0 0 4 4 3 0 0 CR 0 - - - 0/9 CR N N N T0N0M0
98 76 34 20 20 2*2 2*1 1*1 1*1 1*1 PR 15.8 28.6 29.8 22.7 13.8 0.54 0.7 0.76 0.8 0.8 8 4 2 1 1 PR 0 - - - 0/8 CR N P N T0N0M0
198 98 56 42 30 1*1 1*1 1*1 1*1 <1 PR 35.7 36.2 19.3 19.2 15.7 0.58 0.72 0.8 0.85 0.91 10 6 6 3 1 PR 2*2 Y Y NI 005/7 PR P P P T1N2M0
110 90 65 30 28 3*2 1*1 1*1 <1 <1 PR 15.9 32.2 42.1 15.8 19.3 0.4 0.6 0.62 0.62 0.68 10 9 6 2 2 PR 2*1 Y Y NI 0/0 PR N N N T1N0M0
190 58 46 30 25 3*1 3*2 3*1 1*1 <1 PR 63.7 206 55.8 44.9 12.8 0.3 0.58 0.6 0.64 0.7 10 9 6 3 1 PR 3*3 Y Y NI 001/5 PR N N N T2N1M0
240 198 96 54 30 3*2 2*2 2*1 1*1 <1 PR 34.7 15.8 19.2 15.4 23.8 0.43 0.6 0.68 0.78 0.86 10 10 9 5 2 CR 2*2 Y Y NI 0/5 PR P P N T1N0M0
90 54 42 36 24 1*1 1*2 2*1 1*1 <1 PR 28.1 15.8 10.9 49.2 23.9 0.74 0.74 0.77 0.82 0.88 2 3 1 1 1 PR 2*2 Y Y NI 002/6 PR P P P T1N1M0
198 110 56 45 22 2*2 2*2 1*1 1*1 <1 PR 25.4 44.4 7.7 20.4 0 0.45 0.7 0.72 0.78 0 6 5 3 2 0 CR 0 - - NI 0/9 CR P P N T0N0M0
76 54 34 23 20 3*2 2*2 1*1 1*1 1*1 PR 27.3 27.1 26.1 32.1 44.8 0.5 0.53 0.5 0.58 0.6 5 4 3 4 1 PR 2*2 Y Y NI 001/10 PR N N N T1N1M0
108 76 45 30 20 2*2 2*2 1*1 1*1 <1 PR 32.5 35.7 13.2 12 8.8 0.56 0.78 0.82 0.88 0.9 10 8 6 4 2 PR 2*2 Y Y NI 002/10 PR N P N T2N1M0
122 76 34 25 23 1*1 1*1 <1 <1 <1 PR 66.9 20.9 101.8 54.9 80.2 0.59 0.72 0.76 0.78 0.86 5 4 6 2 1 PR 1*1 Y Y NI 001/8 PR P P N T1N1M0
165 78 44 32 22 2*1 1*1 1*1 <1 <1 PR 28.1 15.8 0 0 0 0.6 0.78 0 0 0 7 6 0 0 0 CR 0 - - NI 0/12 CR N N N T0N0M0
86 53 22 0 0 2*1 1*0.50.5*0.5 0 0 CR 28.5 28.3 65.3 73.4 0 0.66 0.85 0.91 0.89 0 3 3 3 1 0 CR 0 - - NI 0/9 CR N P P T0N0M0
122 68 42 12 0 2*2 1*1 <1 0 0 CR 31.1 22.7 26.9 11.9 8.3 0.44 0.68 0.7 0.68 0.78 11 5 1 1 1 PR 1*1 Y Y NI 001/10 PR N P N T1N1M0
56 40 38 42 36 2*3 1*1 1*2 1*1 <1 NR 54.9 23.9 12.8 21.9 23.8 0.76 0.74 0.68 0.68 0.6 3 1 1 1 1 NR 4*4 Y Y NI 0/9 NR N N P T2N0M0
76 54 32 25 20 1*1 1*1 1*1 <1 <1 PR 15.9 32.2 42.1 15.8 19.3 0.45 0.62 0.75 0.8 0.82 6 3 1 1 1 PR 2*2 - - NI 0/14 PR N N N T1N0M0
104 98 76 78 68 1*1 2*1 1*1 <1 <1 NR 65.9 42.8 21.8 16.9 9.3 0.5 0.52 0.68 0.7 0.67 5 2 1 1 1 PR 2*3 Y Y NI 002/9 PR N P P T2N1M0
68 54 45 40 34 0 0 0 0 0 PR 33.1 24.2 69.3 28.2 32.6 0.54 0.58 0.67 0.64 0.62 3 2 1 1 1 PR 3*2 Y Y NI 0/8 PR P P N T2N0M0
78 56 34 32 28 2*1 1*1 1*1 1*1 <1 PR 23.1 66.1 34.8 12.9 9.1 0.78 0.82 0.76 0.8 0.72 6 2 1 1 1 PR 4*3 Y Y NI 0/8 PR N N N T2N0M0
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148 79 56 44 34 2*2 2*2 1*1 <1 <1 PR 18.9 28.2 25.7 0 0 0.38 0.57 0.6 0 0 11 4 2 0 0 CR 0 - - NI 0/9 CR N N P T0N0M0
100 86 64 50 34 3*1 2*1 1*1 <1 <1 PR 57.5 22.9 30.1 44.2 34.8 0.86 0.86 0.75 0.78 0.8 8 6 6 4 4 PR 4*4 Y Y NI 001/8 PR N P N T3N1M0
78 34 20 0 0 1*1 <1 <1 <1 <1 CR 28.9 15.9 17.9 22.9 44.6 0.56 0.72 0.68 0.7 0.78 8 6 3 1 1 PR 0 - - - 0/8 CR N P P T0N0M0
45 40 76 84 90 1*1 1*1 2*1 1*1 1*1 NR 51.3 53.9 68.3 9.8 20.8 0.92 0.88 0.82 0.7 0.64 4 3 2 2 2 NR 11*9 Y Y I 004/13 NR P P P T4BN2M0
66 54 34 24 24 <1 <1 <1 <1 <1 PR 31.5 26.8 19.2 21.8 12.8 0.68 0.76 0.78 0.78 0.8 4 3 1 1 1 PR 2*3 Y Y NI 002/5 PR N P N T2N1M0
56 43 24 20 0 2*2 2*1 1*1 1*1 <1 CR 42.1 23.6 0 0 0 0.46 0 0 0 0 2 1 0 0 0 CR 2*3 Y Y NI 002/5 PR P P P T2N1M0
98 66 45 30 24 2*1 1*1 1*1 <1 <1 PR 23.4 18 16.7 17 23 0.55 0.7 0.75 0.78 0.8 7 3 2 1 1 PR 3*2 Y Y NI 004/6 PR N N N T2N2M0
56 50 46 26 20 2*1 1*1 1*1 <1 <1 PR 34.5 24.7 21 19.8 19 0.52 0.68 0.79 0.79 0.82 9 4 2 1 1 PR 2*2 Y Y NI 002/7 PR N P N T2N1M0
76 21 0 0 0 1*1 1*1 <1 0 0 CR 17.5 39.9 15.6 32.1 23 0.43 0.58 0.6 0.62 0.72 5 1 1 1 1 PR 1*1 N N NI 0/6 PR P P N T1N0M0
56 34 12 0 0 2*1 1*1 <1 0 0 CR 17 18.4 13 9.8 11.1 0.6 0.76 0.78 0.8 0.8 4 4 1 1 1 PR 1*1 N N NI 001/5 PR P P N T1N0M0
74 70 68 70 52 1*1 1*1 <1 <1 <1 NR 14.3 14.1 6.3 5.8 4.9 0.81 0.67 0.65 0.56 0.52 5 3 2 3 4 NR 3*2 Y Y NI 004/12 PR N P N T2N2M0
98 86 74 70 46 3*2 2*2 2*1 <1 <1 PR 10.8 12.7 9.8 12.1 7.6 0.63 0.7 0.68 0.76 0.8 6 3 2 1 1 PR 2*2 Y Y NI 001/11 PR N N N T1N1M0
102 78 56 42 32 2*2 1*2 1*1 <1 <1 PR 34.1 36.6 29.6 24.3 19.1 0.92 0.88 0.85 0.8 0.76 7 3 3 2 3 PR 3*3 Y Y NI 002/8 PR P N N T2N1M0
122 78 46 34 24 1*1 1*1 <1 <1 <1 PR 34.1 58.4 0 0 0 0.56 0.6 0 0 0 8 4 1 1 1 CR 1*1 Y Y NI 004/9 PR N N P T1N2M0
132 100 56 44 32 3*1 3*1 2*2 1*1 <1 PR 10.1 8.9 11.2 15.8 22.9 0.48 0.63 0.68 0.78 0.82 9 3 2 2 1 PR 5*4 Y Y NI 002/9 PR P N N T2N1M0
56 45 32 20 0 2*2 1*2 <1 0 0 CR 8.9 11.1 12.8 21 9.8 0.66 0.87 0.9 0.91 0.9 8 3 2 1 1 PR 3*1 N N NI 0/9 NR P P N T2N0M0
132 86 76 46 24 1*1 2*1 2*2 <1 <1 PR 36.5 22.5 19.8 23.6 21.1 0.7 0.74 0.8 0.82 0.78 9 3 2 2 1 PR 6*3 Y Y NI 007/8 PR P P N T3N3M0
76 54 50 46 34 2*2 2*1 1*1 <1 <1 PR 24.4 18.9 14.8 14 12.8 0.57 0.64 0.78 0.8 0.82 7 4 2 1 1 PR 4*3 Y Y NI 004/9 PR N P N T2N2M0
76 56 38 24 24 2*1 3*2 2*1 1*1 1*1 PR 16.8 21.8 19.7 15.9 20 0.52 0.7 0.76 0.75 0.74 8 3 1 1 1 PR 1*1 N N NI 002/8 PR P P N T1N1M0
102 88 76 68 70 2*1 1*1 1*1 1*1 <1 NR 21.6 18.7 17.6 14.4 9.7 0.9 0.86 0.79 0.82 0.82 9 4 3 1 1 PR 3*2 N N NI 001/9 PR N N N T2N1M0
142 196 46 34 10 1*1 1*1 <1 0 0 PR 87.5 23.6 43.1 12.7 13.8 0.58 0.76 0.78 0.92 0.9 10 3 1 1 1 PR 1*1 Y Y NI 005/11 PR P P N T1N2M0
112 78 46 24 26 1*1 1*1 <1 <1 <1 PR 57.8 43.8 23 12.1 9.7 0.66 0.82 0.8 0.88 0.9 6 5 2 1 1 PR 2*1 Y Y NI 006/7 PR P P N T1N2M0
56 36 30 28 25 2*1 1*1 1*1 1*1 1*1 PR 23.1 19.2 13.8 17.2 11.4 0.67 0.78 0.78 0.8 0.86 8 3 2 1 1 PR 3*2 Y Y NI 001/11 PR N P N T2N1M0
